| Year |
Citation |
Score |
| 2024 |
Lieberman JA, Mendelsohn A, Goldberg TE, Emsley R. Preventing disease progression in schizophrenia: What are we waiting for. Journal of Psychiatric Research. 181: 716-727. PMID 39754992 DOI: 10.1016/j.jpsychires.2024.12.042 |
0.376 |
|
| 2024 |
Torrey EF, Lieberman J. The Underuse of Clozapine and Long-Acting Injectable Antipsychotics. Psychiatric Services (Washington, D.C.). appips20240110. PMID 39380452 DOI: 10.1176/appi.ps.20240110 |
0.368 |
|
| 2022 |
Trubetskoy V, Pardiñas AF, Qi T, Panagiotaropoulou G, Awasthi S, Bigdeli TB, Bryois J, Chen CY, Dennison CA, Hall LS, Lam M, Watanabe K, Frei O, Ge T, Harwood JC, ... Lieberman J, et al. Mapping genomic loci implicates genes and synaptic biology in schizophrenia. Nature. PMID 35396580 DOI: 10.1038/s41586-022-04434-5 |
0.628 |
|
| 2022 |
Stone WS, Phillips MR, Yang LH, Kegeles LS, Susser ES, Lieberman JA. Neurodegenerative model of schizophrenia: Growing evidence to support a revisit. Schizophrenia Research. 243: 154-162. PMID 35344853 DOI: 10.1016/j.schres.2022.03.004 |
0.361 |
|
| 2022 |
First MB, Lieberman JA. How should we diagnose schizophrenia: Don't throw the baby out with the bath water. Schizophrenia Research. 242: 81-83. PMID 35241315 DOI: 10.1016/j.schres.2022.01.024 |
0.31 |
|
| 2021 |
Zoghbi AW, Dhindsa RS, Goldberg TE, Mehralizade A, Motelow JE, Wang X, Alkelai A, Harms MB, Lieberman JA, Markx S, Goldstein DB. High-impact rare genetic variants in severe schizophrenia. Proceedings of the National Academy of Sciences of the United States of America. 118. PMID 34903660 DOI: 10.1073/pnas.2112560118 |
0.4 |
|
| 2021 |
Paul SM, Breier A, Lieberman JA, Brannan SK, Sawchak S, Miller AC. Clinical Trial of New Drug for Schizophrenia. Reply. The New England Journal of Medicine. 384: e105. PMID 34161716 DOI: 10.1056/NEJMc2104965#sa2 |
0.367 |
|
| 2021 |
Lieberman JA, Dishy G. Milestones in the History of Schizophrenia. A Comprehensive Chronology of Schizophrenia Research: What Do We Know and When Did We Know It Psychiatric News. 56. DOI: 10.1176/APPI.PN.2021.1.7 |
0.416 |
|
| 2020 |
Stone WS, Cai B, Liu X, Grivel MM, Yu G, Xu Y, Ouyang X, Chen H, Deng F, Xue F, Li H, Lieberman JA, Keshavan MS, Susser ES, Yang LH, et al. Association Between the Duration of Untreated Psychosis and Selective Cognitive Performance in Community-Dwelling Individuals With Chronic Untreated Schizophrenia in Rural China. Jama Psychiatry. PMID 32639517 DOI: 10.1001/Jamapsychiatry.2020.1619 |
0.458 |
|
| 2020 |
Kantrowitz JT, Grinband J, Goff DC, Lahti AC, Marder SR, Kegeles LS, Girgis RR, Sobeih T, Wall MM, Choo TH, Green MF, Yang YS, Lee J, Horga G, Krystal JH, ... ... Lieberman JA, et al. Proof of mechanism and target engagement of glutamatergic drugs for the treatment of schizophrenia: RCTs of pomaglumetad and TS-134 on ketamine-induced psychotic symptoms and pharmacoBOLD in healthy volunteers. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. PMID 32403118 DOI: 10.1038/S41386-020-0706-Z |
0.379 |
|
| 2020 |
Maes MS, Lu JY, Tiwari AK, Freeman N, de Luca V, Müller DJ, Voineskos AN, Potkin SG, Lieberman JA, Meltzer HY, Remington G, Kennedy JL, Zai CC. Schizophrenia-associated gene dysbindin-1 and tardive dyskinesia. Drug Development Research. PMID 32394511 DOI: 10.1002/Ddr.21681 |
0.486 |
|
| 2020 |
Yoshida K, Maciukiewicz M, Zai CC, Gonçalves VF, Brandl EJ, Lieberman JA, Meltzer HY, Tiwari AK, Kennedy JL, Müller DJ. Association between the -2548G/A polymorphism of the leptin gene and antipsychotic-induced weight gain: Analysis of the CATIE sample and meta-analysis. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 109952. PMID 32335267 DOI: 10.1016/J.Pnpbp.2020.109952 |
0.366 |
|
| 2020 |
Yang LH, Ruiz B, Mandavia AD, Grivel MM, Wong LY, Phillips MR, Keshavan MS, Li H, Lieberman JA, Susser E, Seidman LJ, Stone WS. Advancing study of cognitive impairments for antipsychotic-naïve psychosis comparing high-income versus low- and middle-income countries with a focus on urban China: Systematic review of cognition and study methodology. Schizophrenia Research. PMID 32269004 DOI: 10.1016/J.Schres.2020.01.026 |
0.341 |
|
| 2020 |
Kantrowitz JT, Javitt DC, Freedman R, Sehatpour P, Kegeles LS, Carlson M, Sobeih T, Wall MM, Choo TH, Vail B, Grinband J, Lieberman JA. Double blind, two dose, randomized, placebo-controlled, cross-over clinical trial of the positive allosteric modulator at the alpha7 nicotinic cholinergic receptor AVL-3288 in schizophrenia patients. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. PMID 32015461 DOI: 10.1038/S41386-020-0628-9 |
0.471 |
|
| 2020 |
Clelland CL, Kantrowitz JT, Choo T, Clelland JD, Lieberman JA. Adjunctive sapropterin dihydrochloride treatment in schizophrenia: A positive proof-of-concept, rater-blind, randomized, multivitamin-controlled study. Schizophrenia Research. PMID 31973997 DOI: 10.1016/J.Schres.2019.12.039 |
0.494 |
|
| 2020 |
Correll CU, Davis RE, Weingart M, Saillard J, O'Gorman C, Kane JM, Lieberman JA, Tamminga CA, Mates S, Vanover KE. Efficacy and Safety of Lumateperone for Treatment of Schizophrenia: A Randomized Clinical Trial. Jama Psychiatry. PMID 31913424 DOI: 10.1001/Jamapsychiatry.2019.4379 |
0.523 |
|
| 2020 |
Kraus MS, Gold JM, Barch DM, Walker TM, Chun CA, Buchanan RW, Csernansky JG, Goff DC, Green MF, Jarskog LF, Javitt DC, Kimhy D, Lieberman JA, McEvoy JP, Mesholam-Gately RI, et al. The characteristics of cognitive neuroscience tests in a schizophrenia cognition clinical trial: Psychometric properties and correlations with standard measures. Schizophrenia Research. Cognition. 19: 100161. PMID 31832342 DOI: 10.1016/J.Scog.2019.100161 |
0.339 |
|
| 2020 |
Yoshida K, Maciukiewicz M, Marshe V, Tiwari A, Brandl E, Lieberman J, Meltzer H, Kennedy J, Mueller D. M172. POLYGENIC RISK SCORES ANALYSES IN ANTIPSYCHOTIC-INDUCED WEIGHT GAIN Schizophrenia Bulletin. 46: S202-S202. DOI: 10.1093/Schbul/Sbaa030.484 |
0.359 |
|
| 2019 |
Provenzano FA, Guo J, Wall MM, Feng X, Sigmon HC, Brucato G, First MB, Rothman DL, Girgis RR, Lieberman JA, Small SA. Hippocampal Pathology in Clinical High-Risk Patients and the Onset of Schizophrenia. Biological Psychiatry. PMID 31771861 DOI: 10.1016/J.Biopsych.2019.09.022 |
0.361 |
|
| 2019 |
Brucato G, First MB, Dishy GA, Samuel SS, Xu Q, Wall MM, Small SA, Masucci MD, Lieberman JA, Girgis RR. Recency and intensification of positive symptoms enhance prediction of conversion to syndromal psychosis in clinical high-risk patients. Psychological Medicine. 1-9. PMID 31658912 DOI: 10.1017/S0033291719003040 |
0.384 |
|
| 2019 |
Lieberman JA, Small SA, Girgis RR. Early Detection and Preventive Intervention in Schizophrenia: From Fantasy to Reality. The American Journal of Psychiatry. 176: 794-810. PMID 31569988 DOI: 10.1176/Appi.Ajp.2019.19080865 |
0.485 |
|
| 2019 |
Alkelai A, Greenbaum L, Heinzen EL, Baugh EH, Teitelbaum A, Zhu X, Strous RD, Tatarskyy P, Zai CC, Tiwari AK, Tampakeras M, Freeman N, Müller DJ, Voineskos AN, Lieberman JA, et al. New insights into tardive dyskinesia genetics: Implementation of whole-exome sequencing approach. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 109659. PMID 31153890 DOI: 10.1016/J.Pnpbp.2019.109659 |
0.41 |
|
| 2019 |
Feng X, Provenzano F, Appelbaum PS, Masucci MD, Brucato G, Lieberman JA, Girgis RR. Amygdalar volume and violent ideation in a sample at clinical high-risk for psychosis. Psychiatry Research. Neuroimaging. 287: 60-62. PMID 30991249 DOI: 10.1016/J.Pscychresns.2019.04.003 |
0.316 |
|
| 2019 |
Lawrence RE, Appelbaum PS, Lieberman JA. Are Placebo-Controlled, Relapse Prevention Trials in Schizophrenia Research Still Necessary or Ethical? Jama Psychiatry. PMID 30969331 DOI: 10.1001/jamapsychiatry.2019.0275 |
0.355 |
|
| 2019 |
Fleming LM, Javitt DC, Carter CS, Kantrowitz JT, Girgis RR, Kegeles LS, Ragland JD, Maddock RJ, Lesh TA, Tanase C, Robinson J, Potter WZ, Carlson M, Wall MM, Choo TH, ... ... Lieberman J, et al. A multicenter study of ketamine effects on functional connectivity: Large scale network relationships, hubs and symptom mechanisms. Neuroimage. Clinical. 22: 101739. PMID 30852397 DOI: 10.1016/J.Nicl.2019.101739 |
0.496 |
|
| 2019 |
Bitter I, Lieberman JA, Gaudoux F, Sokoloff P, Groc M, Chavda R, Delsol C, Barthe L, Brunner V, Fabre C, Fagard M, Montagne A, Tonner F. Randomized, double-blind, placebo-controlled study of F17464, a preferential D antagonist, in the treatment of acute exacerbation of schizophrenia. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. PMID 30822774 DOI: 10.1038/S41386-019-0355-2 |
0.404 |
|
| 2019 |
Yoshida K, Kanji S, Maciukiewicz M, Tiwari AK, Gorbovskaya I, Goncalves VF, Zai C, Brandl E, Freeman N, Lieberman JA, Meltzer H, Kennedy JL, Müller DJ. Validation Study In Two Genome-Wide Significant Risk Variants For Antipsychotic Induced Weight Gain European Neuropsychopharmacology. 29. DOI: 10.1016/J.Euroneuro.2017.08.275 |
0.352 |
|
| 2019 |
Abi-Dargham A, Van Snellenberg J, Girgis R, Slifstein M, Javitch J, Lieberman J. 118. The Challenges of Testing D1 Agonists in Schizophrenia Biological Psychiatry. 85: S49. DOI: 10.1016/J.Biopsych.2019.03.132 |
0.452 |
|
| 2019 |
Lieberman J, Goff D, Marder S, Lahti A, Javitt D, Kantrowitz J, Girgis R, Grinband J, Kegeles L, Wall M, Chou T. 117. Biomarker Assessment of Dose Dependent Target Engagement of mGluR-2,3 Partial Agonist for Schizophrenia Treatment Biological Psychiatry. 85: S49. DOI: 10.1016/J.Biopsych.2019.03.131 |
0.453 |
|
| 2018 |
Brucato G, Appelbaum PS, Masucci MD, Rolin S, Wall MM, Levin M, Altschuler R, First MB, Lieberman JA, Girgis RR. Prevalence and phenomenology of violent ideation and behavior among 200 young people at clinical high-risk for psychosis: an emerging model of violence and psychotic illness. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. PMID 30591713 DOI: 10.1038/S41386-018-0304-5 |
0.325 |
|
| 2018 |
Zai CC, Lee FH, Tiwari AK, Lu JY, de Luca V, Maes MS, Herbert D, Shahmirian A, Cheema SY, Zai GC, Atukuri A, Sherman M, Shaikh SA, Tampakeras M, Freeman N, ... ... Lieberman JA, et al. Investigation of the Gene in Tardive Dyskinesia - New Data and Meta-Analysis. Frontiers in Pharmacology. 9: 974. PMID 30283332 DOI: 10.3389/Fphar.2018.00974 |
0.391 |
|
| 2018 |
Lu JY, Tiwari AK, Zai GC, Rastogi A, Shaikh SA, Mueller DJ, Voineskos AN, Potkin SG, Lieberman JA, Meltzer HY, Remington G, Wong AHC, Kennedy JL, Zai CC. Association study of Disrupted-In-Schizophrenia-1 Gene variants and Tardive Dyskinesia. Neuroscience Letters. PMID 30118782 DOI: 10.1016/J.Neulet.2018.08.007 |
0.461 |
|
| 2018 |
Girgis RR, Zoghbi AW, Javitt DC, Lieberman JA. The past and future of novel, non-dopamine-2 receptor therapeutics for schizophrenia: A critical and comprehensive review. Journal of Psychiatric Research. PMID 30055853 DOI: 10.1016/J.Jpsychires.2018.07.006 |
0.49 |
|
| 2018 |
Lieberman JA. Disease modifying effects of antipsychotic drugs in schizophrenia: a clinical and neurobiological perspective. World Psychiatry : Official Journal of the World Psychiatric Association (Wpa). 17: 163-165. PMID 29856557 DOI: 10.1002/Wps.20543 |
0.498 |
|
| 2018 |
Lieberman JA, Girgis RR, Brucato G, Moore H, Provenzano F, Kegeles L, Javitt D, Kantrowitz J, Wall MM, Corcoran CM, Schobel SA, Small SA. Hippocampal dysfunction in the pathophysiology of schizophrenia: a selective review and hypothesis for early detection and intervention. Molecular Psychiatry. PMID 29311665 DOI: 10.1038/Mp.2017.249 |
0.376 |
|
| 2018 |
Girardin FR, Poncet A, Perrier A, Vernaz N, Pletscher M, F Samer C, Lieberman JA, Villard J. Cost-effectiveness of HLA-DQB1/HLA-B pharmacogenetic-guided treatment and blood monitoring in US patients taking clozapine. The Pharmacogenomics Journal. PMID 29298994 DOI: 10.1038/S41397-017-0004-2 |
0.375 |
|
| 2018 |
Maciukiewicz M, Tiwari A, Goncalves V, Zai C, Brandl E, Freeman N, Lieberman J, Meltzer H, Laughlin C, Nurmi E, Kennedy J, Mueller D. F1. GENOME-WIDE ASSOCIATION STUDIES SUGGESTED ASSOCIATION BETWEEN DGKB AND ANTIPSYCHOTIC INDUCED WEIGHT GAIN IN EUROPEANS AND AFRICAN AMERICANS Schizophrenia Bulletin. 44: S218-S218. DOI: 10.1093/Schbul/Sby017.532 |
0.408 |
|
| 2018 |
Frazier JA, McClellan J, Findling RL, Vitiello B, Anderson R, Zablotsky B, Williams E, McNamara NK, Jackson JA, Ritz L, Hlastala SA, Pierson L, Varley JA, Puglia M, Maloney AE, ... ... Lieberman JA, et al. Treatment of Early-Onset Schizophrenia Spectrum disorders (TEOSS) Journal of the American Academy of Child and Adolescent Psychiatry. 46: 969-978. DOI: 10.1093/Med/9780190625085.003.0009 |
0.489 |
|
| 2017 |
Javitt DC, Carter CS, Krystal JH, Kantrowitz JT, Girgis RR, Kegeles LS, Ragland JD, Maddock RJ, Lesh TA, Tanase C, Corlett PR, Rothman DL, Mason G, Qiu M, Robinson J, ... ... Lieberman JA, et al. Utility of Imaging-Based Biomarkers for Glutamate-Targeted Drug Development in Psychotic Disorders: A Randomized Clinical Trial. Jama Psychiatry. PMID 29167877 DOI: 10.1001/Jamapsychiatry.2017.3572 |
0.332 |
|
| 2017 |
Girgis RR, Ciarleglio A, Choo T, Haynes G, Bathon JM, Cremers S, Kantrowitz JT, Lieberman JA, Brown AS. A Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Tocilizumab, an Interleukin-6 Receptor Antibody, for Residual Symptoms in Schizophrenia. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. PMID 29090685 DOI: 10.1038/Npp.2017.258 |
0.438 |
|
| 2017 |
Zoghbi AW, Lieberman JA. Alive but not well: the limited validity but continued utility of the concept of schizophrenia. Psychological Medicine. 1-2. PMID 29072155 DOI: 10.1017/S0033291717001969 |
0.519 |
|
| 2017 |
Zai CC, Tiwari AK, Chowdhury NI, Brandl EJ, Shaikh SA, Freeman N, Lieberman JA, Meltzer HY, Kennedy JL, Müller DJ. Association Study of Serotonin 3 Receptor Subunit Gene Variants in Antipsychotic-Induced Weight Gain. Neuropsychobiology. 74: 169-175. PMID 28531893 DOI: 10.1159/000457903 |
0.432 |
|
| 2017 |
Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthøj B, Gattaz WF, Thibaut F, Möller HJ. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia - a short version for primary care. International Journal of Psychiatry in Clinical Practice. 1-9. PMID 28498090 DOI: 10.1080/13651501.2017.1291839 |
0.477 |
|
| 2017 |
Goff DC, Falkai P, Fleischhacker WW, Girgis RR, Kahn RM, Uchida H, Zhao J, Lieberman JA. The Long-Term Effects of Antipsychotic Medication on Clinical Course in Schizophrenia. The American Journal of Psychiatry. appiajp201716091016. PMID 28472900 DOI: 10.1176/Appi.Ajp.2017.16091016 |
0.473 |
|
| 2017 |
Stroup TS, Lieberman JA. Raising the standard of care for schizophrenia is an achievable goal. The Australian and New Zealand Journal of Psychiatry. 4867417700277. PMID 28374601 DOI: 10.1177/0004867417700277 |
0.663 |
|
| 2017 |
Brucato G, Masucci MD, Arndt LY, Ben-David S, Colibazzi T, Corcoran CM, Crumbley AH, Crump FM, Gill KE, Kimhy D, Lister A, Schobel SA, Yang LH, Lieberman JA, Girgis RR. Baseline demographics, clinical features and predictors of conversion among 200 individuals in a longitudinal prospective psychosis-risk cohort. Psychological Medicine. 1-13. PMID 28249639 DOI: 10.1017/S0033291717000319 |
0.313 |
|
| 2017 |
Lanning R, Lett TA, Tiwari AK, Brandl EJ, de Luca V, Voineskos AN, Potkin SG, Lieberman JA, Meltzer HY, Müller DJ, Remington G, Kennedy JL, Zai CC. Association study between the neurexin-1 gene and tardive dyskinesia. Human Psychopharmacology. 32. PMID 28120489 DOI: 10.1002/Hup.2568 |
0.392 |
|
| 2017 |
Chen C, Tiwari A, Zai C, Tylor D, Potkin S, Meltzer H, Lieberman J, Mueller D, Kennedy J. SU3. Preliminary Study for Association of Genome-Wide Significant Glutamate Receptor Schizophrenia Risk Variants With Clozapine Response Schizophrenia Bulletin. 43: S161-S162. DOI: 10.1093/Schbul/Sbx024.002 |
0.452 |
|
| 2017 |
Kennedy JL, Huang E, Tiwari AK, Zai C, Gonçalves V, Potkin S, Lieberman J, Meltzer H. Preliminary Model For The Genetic Prediction Of Clozapine Response European Neuropsychopharmacology. 27: S456. DOI: 10.1016/J.Euroneuro.2016.09.526 |
0.347 |
|
| 2016 |
Lawrie SM, O'Donovan MC, Saks E, Burns T, Lieberman JA. Towards diagnostic markers for the psychoses. The Lancet. Psychiatry. 3: 375-85. PMID 27063388 DOI: 10.1016/S2215-0366(16)00021-3 |
0.396 |
|
| 2016 |
Van Snellenberg JX, Girgis RR, Horga G, van de Giessen E, Slifstein M, Ojeil N, Weinstein JJ, Moore H, Lieberman JA, Shohamy D, Smith EE, Abi-Dargham A. Mechanisms of Working Memory Impairment in Schizophrenia. Biological Psychiatry. PMID 27056754 DOI: 10.1016/J.Biopsych.2016.02.017 |
0.458 |
|
| 2016 |
Kantrowitz JT, Sharif Z, Medalia A, Keefe RS, Harvey P, Bruder G, Barch DM, Choo T, Lee S, Lieberman JA. A multicenter, rater-blinded, randomized controlled study of auditory processing-focused cognitive remediation combined with open-label lurasidone in patients with schizophrenia and schizoaffective disorder. The Journal of Clinical Psychiatry. PMID 27035157 DOI: 10.4088/Jcp.15M09998 |
0.408 |
|
| 2016 |
Girgis RR, Van Snellenberg JX, Glass A, Kegeles LS, Thompson JL, Wall M, Cho RY, Carter CS, Slifstein M, Abi-Dargham A, Lieberman JA. A proof-of-concept, randomized controlled trial of DAR-0100A, a dopamine-1 receptor agonist, for cognitive enhancement in schizophrenia. Journal of Psychopharmacology (Oxford, England). PMID 26966119 DOI: 10.1177/0269881116636120 |
0.397 |
|
| 2016 |
Taylor DL, Tiwari AK, Lieberman JA, Potkin SG, Meltzer HY, Knight J, Remington G, Müller DJ, Kennedy JL. Genetic association analysis of N-methyl-d-aspartate receptor subunit gene GRIN2B and clinical response to clozapine. Human Psychopharmacology. PMID 26876050 DOI: 10.1002/Hup.2519 |
0.472 |
|
| 2016 |
Huang E, Zai CC, Lisoway A, Maciukiewicz M, Felsky D, Tiwari AK, Bishop JR, Ikeda M, Molero P, Ortuno F, Porcelli S, Samochowiec J, Mierzejewski P, Gao S, Crespo-Facorro B, ... ... Lieberman JA, et al. Catechol-O-methyltransferase Val158Met polymorphism and clinical response to antipsychotic treatment in schizophrenia and schizo-affective disorder patients: a meta-analysis. The International Journal of Neuropsychopharmacology / Official Scientific Journal of the Collegium Internationale Neuropsychopharmacologicum (Cinp). PMID 26745992 DOI: 10.1093/Ijnp/Pyv132 |
0.417 |
|
| 2016 |
Huang E, Maciukiewicz M, Zai CC, Tiwari AK, Li J, Potkin SG, Lieberman JA, Meltzer HY, Müller DJ, Kennedy JL. Preliminary evidence for association of genome-wide significant DRD2 schizophrenia risk variant with clozapine response. Pharmacogenomics. 17: 103-9. PMID 26666695 DOI: 10.2217/Pgs.15.155 |
0.451 |
|
| 2015 |
Tiwari AK, Brandl EJ, Zai CC, Goncalves VF, Chowdhury NI, Freeman N, Lieberman JA, Meltzer HY, Kennedy JL, Müller DJ. Association of orexin receptor polymorphisms with antipsychotic-induced weight gain. The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry. 1-9. PMID 26447462 DOI: 10.3109/15622975.2015.1076173 |
0.33 |
|
| 2015 |
Lieberman JA, Davis RE, Correll CU, Goff DC, Kane JM, Tamminga CA, Mates S, Vanover KE. ITI-007 for the Treatment of Schizophrenia: A 4-Week Randomized, Double-Blind, Controlled Trial. Biological Psychiatry. PMID 26444072 DOI: 10.1016/J.Biopsych.2015.08.026 |
0.486 |
|
| 2015 |
Lee SH, Byrne EM, Hultman CM, Kähler A, Vinkhuyzen AA, Ripke S, Andreassen OA, Frisell T, Gusev A, Hu X, Karlsson R, Mantzioris VX, McGrath JJ, Mehta D, Stahl EA, ... ... Lieberman JA, et al. New data and an old puzzle: the negative association between schizophrenia and rheumatoid arthritis. International Journal of Epidemiology. PMID 26286434 DOI: 10.1093/Ije/Dyv136 |
0.407 |
|
| 2015 |
Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthøj B, Gattaz WF, Thibaut F, Möller HJ. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia. Part 3: Update 2015 Management of special circumstances: Depression, Suicidality, substance use disorders and pregnancy and lactation. The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry. 16: 142-70. PMID 25822804 DOI: 10.3109/15622975.2015.1009163 |
0.47 |
|
| 2015 |
Dixon LB, Goldman HH, Bennett ME, Wang Y, McNamara KA, Mendon SJ, Goldstein AB, Choi CW, Lee RJ, Lieberman JA, Essock SM. Implementing Coordinated Specialty Care for Early Psychosis: The RAISE Connection Program. Psychiatric Services (Washington, D.C.). 66: 691-8. PMID 25772764 DOI: 10.1176/Appi.Ps.201400281 |
0.351 |
|
| 2015 |
Jarskog LF, Lowy MT, Grove RA, Keefe RS, Horrigan JP, Ball MP, Breier A, Buchanan RW, Carter CS, Csernansky JG, Goff DC, Green MF, Kantrowitz JT, Keshavan MS, Laurelle M, ... Lieberman JA, et al. A Phase II study of a histamine H₃ receptor antagonist GSK239512 for cognitive impairment in stable schizophrenia subjects on antipsychotic therapy. Schizophrenia Research. 164: 136-42. PMID 25728831 DOI: 10.1016/J.Schres.2015.01.041 |
0.449 |
|
| 2015 |
Slifstein M, van de Giessen E, Van Snellenberg J, Thompson JL, Narendran R, Gil R, Hackett E, Girgis R, Ojeil N, Moore H, D'Souza D, Malison RT, Huang Y, Lim K, Nabulsi N, ... ... Lieberman JA, et al. Deficits in prefrontal cortical and extrastriatal dopamine release in schizophrenia: a positron emission tomographic functional magnetic resonance imaging study. Jama Psychiatry. 72: 316-24. PMID 25651194 DOI: 10.1001/Jamapsychiatry.2014.2414 |
0.407 |
|
| 2015 |
Pouget JG, Gonçalves VF, Nurmi EL, P Laughlin C, Mallya KS, McCracken JT, Aman MG, McDougle CJ, Scahill L, Misener VL, Tiwari AK, Zai CC, Brandl EJ, Felsky D, Leung AQ, ... Lieberman JA, et al. Investigation of TSPO variants in schizophrenia and antipsychotic treatment outcomes. Pharmacogenomics. 16: 5-22. PMID 25560467 DOI: 10.2217/Pgs.14.158 |
0.527 |
|
| 2015 |
Zai CC, Tiwari AK, Chowdhury NI, Brandl EJ, Shaikh SA, Freeman N, Lieberman JA, Meltzer HY, Müller DJ, Kennedy JL. Association study of GABAA α2 receptor subunit gene variants in antipsychotic-associated weight gain. Journal of Clinical Psychopharmacology. 35: 7-12. PMID 25514066 DOI: 10.1097/Jcp.0000000000000261 |
0.388 |
|
| 2015 |
Dixon L, Lieberman J. Early psychosis intervention services: a work in progress. Schizophrenia Bulletin. 41: 23-4. PMID 25332408 DOI: 10.1093/Schbul/Sbu143 |
0.364 |
|
| 2015 |
Rosell DR, Zaluda LC, McClure MM, Perez-Rodriguez MM, Strike KS, Barch DM, Harvey PD, Girgis RR, Hazlett EA, Mailman RB, Abi-Dargham A, Lieberman JA, Siever LJ. Effects of the D1 dopamine receptor agonist dihydrexidine (DAR-0100A) on working memory in schizotypal personality disorder. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 40: 446-53. PMID 25074637 DOI: 10.1038/Npp.2014.192 |
0.368 |
|
| 2015 |
Durgam S, Earley W, Li R, Li D, Lu K, Laszlovszky I, Fleischhacker W, Lieberman J. P.3.d.057 Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: a double-blind, placebo-controlled trial European Neuropsychopharmacology. 25: S512-S513. DOI: 10.1016/S0924-977X(15)30705-7 |
0.335 |
|
| 2014 |
Rutherford BR, Pott E, Tandler JM, Wall MM, Roose SP, Lieberman JA. Placebo response in antipsychotic clinical trials: a meta-analysis. Jama Psychiatry. 71: 1409-21. PMID 25321611 DOI: 10.1001/Jamapsychiatry.2014.1319 |
0.317 |
|
| 2014 |
Ballon JS, Pajvani U, Freyberg Z, Leibel RL, Lieberman JA. Molecular pathophysiology of metabolic effects of antipsychotic medications. Trends in Endocrinology and Metabolism: Tem. 25: 593-600. PMID 25190097 DOI: 10.1016/J.Tem.2014.07.004 |
0.368 |
|
| 2014 |
Goldstein JI, Jarskog LF, Hilliard C, Alfirevic A, Duncan L, Fourches D, Huang H, Lek M, Neale BM, Ripke S, Shianna K, Szatkiewicz JP, Tropsha A, van den Oord EJ, Cascorbi I, ... ... Lieberman JA, et al. Clozapine-induced agranulocytosis is associated with rare HLA-DQB1 and HLA-B alleles. Nature Communications. 5: 4757. PMID 25187353 DOI: 10.1038/Ncomms5757 |
0.32 |
|
| 2014 |
Brandl EJ, Tiwari AK, Zai CC, Chowdhury NI, Lieberman JA, Meltzer HY, Kennedy JL, Müller DJ. No evidence for a role of the peroxisome proliferator-activated receptor gamma (PPARG) and adiponectin (ADIPOQ) genes in antipsychotic-induced weight gain. Psychiatry Research. 219: 255-60. PMID 24953421 DOI: 10.1016/J.Psychres.2014.05.031 |
0.352 |
|
| 2014 |
Gagliano SA, Tiwari AK, Freeman N, Lieberman JA, Meltzer HY, Kennedy JL, Knight J, Müller DJ. Protein kinase cAMP-dependent regulatory type II beta (PRKAR2B) gene variants in antipsychotic-induced weight gain. Human Psychopharmacology. 29: 330-5. PMID 24737441 DOI: 10.1002/Hup.2407 |
0.423 |
|
| 2014 |
Graham KA, Keefe RS, Lieberman JA, Calikoglu AS, Lansing KM, Perkins DO. Relationship of low vitamin D status with positive, negative and cognitive symptom domains in people with first-episode schizophrenia. Early Intervention in Psychiatry. PMID 24612563 DOI: 10.1111/Eip.12122 |
0.419 |
|
| 2014 |
Chowdhury NI, Souza RP, Tiwari AK, Brandl EJ, Sicard M, Meltzer HY, Lieberman JA, Kennedy JL, Müller DJ. Investigation of melanocortin system gene variants in antipsychotic-induced weight gain. The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry. 15: 251-8. PMID 24564533 DOI: 10.3109/15622975.2013.858827 |
0.365 |
|
| 2014 |
Poels EM, Kegeles LS, Kantrowitz JT, Javitt DC, Lieberman JA, Abi-Dargham A, Girgis RR. Glutamatergic abnormalities in schizophrenia: a review of proton MRS findings. Schizophrenia Research. 152: 325-32. PMID 24418122 DOI: 10.1016/J.Schres.2013.12.013 |
0.377 |
|
| 2014 |
Gonçalves VF, Zai CC, Tiwari AK, Brandl EJ, Derkach A, Meltzer HY, Lieberman JA, Müller DJ, Sun L, Kennedy JL. A hypothesis-driven association study of 28 nuclear-encoded mitochondrial genes with antipsychotic-induced weight gain in schizophrenia. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 39: 1347-54. PMID 24196945 DOI: 10.1038/Npp.2013.312 |
0.396 |
|
| 2014 |
Siever LJ, Rosell D, McClure M, Strike K, Barch DM, Harvey P, Girgis R, Lieberman J, Giakoumaki S, Bitsios P, Roussos P, Haroutunian V. THE D1 RECEPTOR AND COGNITION AND TRIAL OF A NOVEL D1 AGONIST IN THE SCHIZOPHRENIA SPECTRUM Schizophrenia Research. 153: S5-S6. DOI: 10.1016/S0920-9964(14)70017-9 |
0.391 |
|
| 2013 |
Zai CC, Tiwari AK, Mazzoco M, de Luca V, Müller DJ, Shaikh SA, Lohoff FW, Freeman N, Voineskos AN, Potkin SG, Lieberman JA, Meltzer HY, Remington G, Kennedy JL. Association study of the vesicular monoamine transporter gene SLC18A2 with tardive dyskinesia. Journal of Psychiatric Research. 47: 1760-5. PMID 24018103 DOI: 10.1016/J.Jpsychires.2013.07.025 |
0.378 |
|
| 2013 |
Lieberman JA, Dixon LB, Goldman HH. Early detection and intervention in schizophrenia: a new therapeutic model. Jama. 310: 689-90. PMID 23989167 DOI: 10.1001/Jama.2013.8804 |
0.433 |
|
| 2013 |
Lee SH, Ripke S, Neale BM, Faraone SV, Purcell SM, Perlis RH, Mowry BJ, Thapar A, Goddard ME, Witte JS, Absher D, Agartz I, Akil H, Amin F, ... ... Lieberman JA, et al. Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. Nature Genetics. 45: 984-94. PMID 23933821 DOI: 10.1038/Ng.2711 |
0.591 |
|
| 2013 |
Chan LF, Zai C, Monda M, Potkin S, Kennedy JL, Remington G, Lieberman J, Meltzer HY, De Luca V. Role of ethnicity in antipsychotic-induced weight gain and tardive dyskinesia: genes or environment? Pharmacogenomics. 14: 1273-81. PMID 23930674 DOI: 10.2217/Pgs.13.127 |
0.339 |
|
| 2013 |
Jarskog LF, Hamer RM, Catellier DJ, Stewart DD, Lavange L, Ray N, Golden LH, Lieberman JA, Stroup TS. Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder. The American Journal of Psychiatry. 170: 1032-40. PMID 23846733 DOI: 10.1176/Appi.Ajp.2013.12010127 |
0.67 |
|
| 2013 |
Schobel SA, Chaudhury NH, Khan UA, Paniagua B, Styner MA, Asllani I, Inbar BP, Corcoran CM, Lieberman JA, Moore H, Small SA. Imaging patients with psychosis and a mouse model establishes a spreading pattern of hippocampal dysfunction and implicates glutamate as a driver. Neuron. 78: 81-93. PMID 23583108 DOI: 10.1016/J.Neuron.2013.02.011 |
0.36 |
|
| 2013 |
Lett TA, Chakravarty MM, Chakavarty MM, Felsky D, Brandl EJ, Tiwari AK, Gonçalves VF, Rajji TK, Daskalakis ZJ, Meltzer HY, Lieberman JA, Lerch JP, Mulsant BH, Kennedy JL, Voineskos AN. The genome-wide supported microRNA-137 variant predicts phenotypic heterogeneity within schizophrenia. Molecular Psychiatry. 18: 443-50. PMID 23459466 DOI: 10.1038/Mp.2013.17 |
0.345 |
|
| 2013 |
Colibazzi T, Wexler BE, Bansal R, Hao X, Liu J, Sanchez-Peña J, Corcoran C, Lieberman JA, Peterson BS. Anatomical abnormalities in gray and white matter of the cortical surface in persons with schizophrenia. Plos One. 8: e55783. PMID 23418459 DOI: 10.1371/Journal.Pone.0055783 |
0.381 |
|
| 2013 |
Brandl EJ, Tiwari AK, Lett TA, Shaikh SA, Lieberman JA, Meltzer HY, Kennedy JL, Müller DJ. Exploratory study on association of genetic variation in TBC1D1 with antipsychotic-induced weight gain. Human Psychopharmacology. 28: 183-7. PMID 23364847 DOI: 10.1002/Hup.2288 |
0.372 |
|
| 2013 |
Jarskog LF, Dong Z, Kangarlu A, Colibazzi T, Girgis RR, Kegeles LS, Barch DM, Buchanan RW, Csernansky JG, Goff DC, Harms MP, Javitt DC, Keefe RS, McEvoy JP, McMahon RP, ... ... Lieberman JA, et al. Effects of davunetide on N-acetylaspartate and choline in dorsolateral prefrontal cortex in patients with schizophrenia. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 38: 1245-52. PMID 23325325 DOI: 10.1038/Npp.2013.23 |
0.461 |
|
| 2013 |
Lieberman JA, Dunbar G, Segreti AC, Girgis RR, Seoane F, Beaver JS, Duan N, Hosford DA. A randomized exploratory trial of an α-7 nicotinic receptor agonist (TC-5619) for cognitive enhancement in schizophrenia. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 38: 968-75. PMID 23303043 DOI: 10.1038/Npp.2012.259 |
0.449 |
|
| 2013 |
Tiwari AK, Brandl EJ, Weber C, Likhodi O, Zai CC, Hahn MK, Lieberman JA, Meltzer HY, Kennedy JL, Müller DJ. Association of a functional polymorphism in neuropeptide Y with antipsychotic-induced weight gain in schizophrenia patients. Journal of Clinical Psychopharmacology. 33: 11-7. PMID 23277265 DOI: 10.1097/Jcp.0B013E31827D145A |
0.37 |
|
| 2013 |
Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, Thibaut F, Möller HJ. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry. 14: 2-44. PMID 23216388 DOI: 10.3109/15622975.2012.739708 |
0.477 |
|
| 2013 |
McClure RK, Styner M, Maltbie E, Lieberman JA, Gouttard S, Gerig G, Shi X, Zhu H. Localized differences in caudate and hippocampal shape are associated with schizophrenia but not antipsychotic type. Psychiatry Research. 211: 1-10. PMID 23142194 DOI: 10.1016/J.Pscychresns.2012.07.001 |
0.466 |
|
| 2013 |
Huey ED, Nagy PL, Rodriguez-Murillo L, Manoochehri M, Goldman J, Lieberman J, Karayiorgou M, Mayeux R. C9ORF72 repeat expansions not detected in a group of patients with schizophrenia. Neurobiology of Aging. 34: 1309.e9-10. PMID 23036583 DOI: 10.1016/J.Neurobiolaging.2012.08.011 |
0.486 |
|
| 2013 |
Nowrouzi B, Souza RP, Zai C, Shinkai T, Monda M, Lieberman J, Volvaka J, Meltzer HY, Kennedy JL, De Luca V. Finite mixture regression model analysis on antipsychotics induced weight gain: investigation of the role of the serotonergic genes. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 23: 224-8. PMID 22840963 DOI: 10.1016/J.Euroneuro.2012.05.008 |
0.337 |
|
| 2013 |
Crowley JJ, Hilliard CE, Kim Y, Morgan MB, Lewis LR, Muzny DM, Hawes AC, Sabo A, Wheeler DA, Lieberman JA, Sullivan PF, Gibbs RA. Deep resequencing and association analysis of schizophrenia candidate genes. Molecular Psychiatry. 18: 138-40. PMID 22472875 DOI: 10.1038/Mp.2012.28 |
0.375 |
|
| 2013 |
Colibazzi T, Wexler BE, Bansal R, Hao X, Liu J, Sanchez-Peña J, Corcoran C, Lieberman JA, Peterson BS. Correction: Anatomical Abnormalities in Gray and White Matter of the Cortical Surface in Persons with Schizophrenia Plos One. 8. DOI: 10.1371/annotation/52ec57b7-e60d-40a8-b4fb-9bce5f9f9b40 |
0.308 |
|
| 2013 |
Lieberman J. Early Detection of Schizophrenia: The Time Is Now Psychiatric News. 48: 1-1. DOI: 10.1176/APPI.PN.2013.8B27 |
0.366 |
|
| 2013 |
Lett TA, Chakravarty MM, Felsky D, Brandl EJ, Tiwari AK, Gonçalves VF, Rajji TK, Daskalakis ZJ, Meltzer HY, Lieberman JA, Lerch JP, Mulsant BH, Kennedy JL, Voineskos AN. Erratum: The genome-wide supported microRNA-137 variant predicts phenotypic heterogeneity within schizophrenia (Molecular Psychiatry (2013) DOI: 10.1038/mp.2013.17) Molecular Psychiatry. 18. DOI: 10.1038/Mp.2013.39 |
0.31 |
|
| 2013 |
Lieberman J, Pikalov A, Hsu J, Cucchiaro J, Werner P, Grossman F, Loebel A. P.3.d.051 Lurasidone in the treatment of early-stage schizophrenia: a post-hoc analysis of three pooled acute treatment studies European Neuropsychopharmacology. 23. DOI: 10.1016/S0924-977X(13)70774-0 |
0.432 |
|
| 2013 |
Lieberman J, Cutler A, Wan S, Migliore R, Ruth A, Laszlovszky I, Nemeth G, Durgam S. P.3.d.033 Cariprazine in acute exacerbation of schizophrenia: a fixed-dose, randomised, double-blind, placebo- and active-controlled trial European Neuropsychopharmacology. 23: S477-S478. DOI: 10.1016/S0924-977X(13)70756-9 |
0.301 |
|
| 2013 |
Lieberman J, Pikalov A, Hsu J, Cucchiaro J, Werner P, Grossman F, Loebel A. 1051 – Lurasidone in the treatment of early-stage schizophrenia: a post-hoc analysis of three pooled acute treatment studies European Psychiatry. 28: 1. DOI: 10.1016/S0924-9338(13)76171-6 |
0.5 |
|
| 2012 |
Mamah D, Harms MP, Barch D, Styner M, Lieberman JA, Wang L. Hippocampal shape and volume changes with antipsychotics in early stage psychotic illness. Frontiers in Psychiatry. 3: 96. PMID 23162479 DOI: 10.3389/Fpsyt.2012.00096 |
0.372 |
|
| 2012 |
Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, Thibaut F, Möller HJ. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry. 13: 318-78. PMID 22834451 DOI: 10.3109/15622975.2012.696143 |
0.486 |
|
| 2012 |
Müller DJ, Brandl EJ, Hwang R, Tiwari AK, Sturgess JE, Zai CC, Lieberman JA, Kennedy JL, Richter MA. The AmpliChip® CYP450 test and response to treatment in schizophrenia and obsessive compulsive disorder: a pilot study and focus on cases with abnormal CYP2D6 drug metabolism. Genetic Testing and Molecular Biomarkers. 16: 897-903. PMID 22775532 DOI: 10.1089/Gtmb.2011.0327 |
0.365 |
|
| 2012 |
Hirata Y, Zai CC, Souza RP, Lieberman JA, Meltzer HY, Kennedy JL. Association study of GRIK1 gene polymorphisms in schizophrenia: case-control and family-based studies. Human Psychopharmacology. 27: 345-51. PMID 22730074 DOI: 10.1002/Hup.2233 |
0.435 |
|
| 2012 |
Zai GC, Zai CC, Chowdhury NI, Tiwari AK, Souza RP, Lieberman JA, Meltzer HY, Potkin SG, Müller DJ, Kennedy JL. The role of brain-derived neurotrophic factor (BDNF) gene variants in antipsychotic response and antipsychotic-induced weight gain. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 39: 96-101. PMID 22642961 DOI: 10.1016/J.Pnpbp.2012.05.014 |
0.402 |
|
| 2012 |
Frazier JA, Giuliano AJ, Johnson JL, Yakutis L, Youngstrom EA, Breiger D, Sikich L, Findling RL, McClellan J, Hamer RM, Vitiello B, Lieberman JA, Hooper SR. Neurocognitive outcomes in the Treatment of Early-Onset Schizophrenia Spectrum Disorders study. Journal of the American Academy of Child and Adolescent Psychiatry. 51: 496-505. PMID 22525956 DOI: 10.1016/J.Jaac.2012.02.001 |
0.484 |
|
| 2012 |
Souza RP, Tiwari AK, Chowdhury NI, Ceddia RB, Lieberman JA, Meltzer HY, Kennedy JL, Müller DJ. Association study between variants of AMP-activated protein kinase catalytic and regulatory subunit genes with antipsychotic-induced weight gain. Journal of Psychiatric Research. 46: 462-8. PMID 22305490 DOI: 10.1016/J.Jpsychires.2012.01.010 |
0.364 |
|
| 2012 |
Hwang R, Tiwari AK, Zai CC, Felsky D, Remington E, Wallace T, Tong RP, Souza RP, Oh G, Potkin SG, Lieberman JA, Meltzer HY, Kennedy JL. Dopamine D4 and D5 receptor gene variant effects on clozapine response in schizophrenia: replication and exploration. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 37: 62-75. PMID 22203087 DOI: 10.1016/J.Pnpbp.2011.11.018 |
0.343 |
|
| 2012 |
Javitt DC, Buchanan RW, Keefe RS, Kern R, McMahon RP, Green MF, Lieberman J, Goff DC, Csernansky JG, McEvoy JP, Jarskog F, Seidman LJ, Gold JM, Kimhy D, Nolan KS, et al. Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia. Schizophrenia Research. 136: 25-31. PMID 22169248 DOI: 10.1016/J.Schres.2011.11.001 |
0.459 |
|
| 2012 |
Olfson M, Gerhard T, Huang C, Lieberman JA, Bobo WV, Crystal S. Comparative effectiveness of second-generation antipsychotic medications in early-onset schizophrenia. Schizophrenia Bulletin. 38: 845-53. PMID 21307041 DOI: 10.1093/Schbul/Sbq172 |
0.457 |
|
| 2012 |
Aberg K, Adkins DE, Liu Y, McClay JL, Bukszár J, Jia P, Zhao Z, Perkins D, Stroup TS, Lieberman JA, Sullivan PF, van den Oord EJ. Genome-wide association study of antipsychotic-induced QTc interval prolongation. The Pharmacogenomics Journal. 12: 165-72. PMID 20921969 DOI: 10.1038/Tpj.2010.76 |
0.58 |
|
| 2012 |
Müller DJ, Zai CC, Sicard M, Remington E, Souza RP, Tiwari AK, Hwang R, Likhodi O, Shaikh S, Freeman N, Arenovich T, Heinz A, Meltzer HY, Lieberman JA, Kennedy JL. Systematic analysis of dopamine receptor genes (DRD1-DRD5) in antipsychotic-induced weight gain. The Pharmacogenomics Journal. 12: 156-64. PMID 20714340 DOI: 10.1038/Tpj.2010.65 |
0.309 |
|
| 2012 |
Rosenheck R, Swartz M, McEvoy J, Stroup TS, Davis S, Keefe RS, Hsiao J, Lieberman J. Second-generation antipsychotics: reviewing the cost-effectiveness component of the CATIE trial. Expert Review of Pharmacoeconomics & Outcomes Research. 7: 103-11. PMID 20528436 DOI: 10.1586/14737167.7.2.103 |
0.668 |
|
| 2012 |
Lieberman JA. Treatment of Schizophrenia: Current Capability, Future Promise Psychiatric News. 47: 28-28. DOI: 10.1176/pn.47.3.psychnews_47_3_28-a |
0.396 |
|
| 2011 |
Davis SM, Stroup TS, Koch GG, Davis CE, Rosenheck RA, Lieberman JA. Time to All-cause Treatment Discontinuation as the Primary Outcome in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Study. Statistics in Biopharmaceutical Research. 3: 253-265. PMID 31031886 DOI: 10.1198/Sbr.2011.10013 |
0.604 |
|
| 2011 |
Roberts CE, Mortenson LY, Merrill DB, Rafizadeh N, Smith TE, Lieberman JA. Successful rechallenge with clozapine after eosinophilia. The American Journal of Psychiatry. 168: 1147-51. PMID 22193601 DOI: 10.1176/Appi.Ajp.2010.10040519 |
0.34 |
|
| 2011 |
Tiwari HK, Patki A, Lieberman J, Stroup TS, Allison DB, Leibel RL, Chung WK. Association of Allelic Variation in Genes Mediating Aspects of Energy Homeostasis with Weight Gain during Administration of Antipsychotic Drugs (CATIE Study). Frontiers in Genetics. 2: 56. PMID 22039372 DOI: 10.3389/Fgene.2011.00056 |
0.63 |
|
| 2011 |
Marder SR, Roth B, Sullivan PF, Scolnick EM, Nestler EJ, Geyer MA, Welnberger DR, Karayiorgou M, Guidotti A, Gingrich J, Akbarian S, Buchanan RW, Lieberman JA, Conn PJ, Haggarty SJ, et al. Advancing drug discovery for schizophrenia. Annals of the New York Academy of Sciences. 1236: 30-43. PMID 22032400 DOI: 10.1111/J.1749-6632.2011.06216.X |
0.496 |
|
| 2011 |
Lett TA, Tiwari AK, Meltzer HY, Lieberman JA, Potkin SG, Voineskos AN, Kennedy JL, Müller DJ. The putative functional rs1045881 marker of neurexin-1 in schizophrenia and clozapine response. Schizophrenia Research. 132: 121-4. PMID 21890328 DOI: 10.1016/J.Schres.2011.08.007 |
0.435 |
|
| 2011 |
Lieberman JA, Stroup TS. The NIMH-CATIE Schizophrenia Study: what did we learn? The American Journal of Psychiatry. 168: 770-5. PMID 21813492 DOI: 10.1176/Appi.Ajp.2011.11010039 |
0.639 |
|
| 2011 |
Stroup TS, McEvoy JP, Ring KD, Hamer RH, LaVange LM, Swartz MS, Rosenheck RA, Perkins DO, Nussbaum AM, Lieberman JA. A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP). The American Journal of Psychiatry. 168: 947-56. PMID 21768610 DOI: 10.1176/Appi.Ajp.2011.10111609 |
0.598 |
|
| 2011 |
Shi X, Ibrahim JG, Lieberman J, Styner M, Zhu H. TWO-STAGE EMPIRICAL LIKELIHOOD FOR LONGITUDINAL NEUROIMAGING DATA. The Annals of Applied Statistics. 5: 1132-1158. PMID 21765885 DOI: 10.1214/11-Aoas480 |
0.373 |
|
| 2011 |
Stroup TS, Appelbaum PS, Gu H, Hays S, Swartz MS, Keefe RS, Kim SY, Manschreck TC, Boshes RA, McEvoy JP, Lieberman JA. Longitudinal consent-related abilities among research participants with schizophrenia: results from the CATIE study. Schizophrenia Research. 130: 47-52. PMID 21561740 DOI: 10.1016/J.Schres.2011.04.012 |
0.645 |
|
| 2011 |
Yolken RH, Torrey EF, Lieberman JA, Yang S, Dickerson FB. Serological evidence of exposure to Herpes Simplex Virus type 1 is associated with cognitive deficits in the CATIE schizophrenia sample. Schizophrenia Research. 128: 61-5. PMID 21353483 DOI: 10.1016/J.Schres.2011.01.020 |
0.411 |
|
| 2011 |
Hermes E, Nasrallah H, Davis V, Meyer J, McEvoy J, Goff D, Davis S, Stroup TS, Swartz M, Lieberman J, Rosenheck R. The association between weight change and symptom reduction in the CATIE schizophrenia trial. Schizophrenia Research. 128: 166-70. PMID 21334853 DOI: 10.1016/J.Schres.2011.01.022 |
0.643 |
|
| 2011 |
Souza RP, Meltzer HY, Lieberman JA, Voineskos AN, Remington G, Kennedy JL. Prolactin as a biomarker for treatment response and tardive dyskinesia in schizophrenia subjects: old thoughts revisited from a genetic perspective. Human Psychopharmacology. 26: 21-7. PMID 21305610 DOI: 10.1002/Hup.1161 |
0.423 |
|
| 2011 |
Girgis RR, Phillips MR, Li X, Li K, Jiang H, Wu C, Duan N, Niu Y, Lieberman JA. Clozapine v. chlorpromazine in treatment-naive, first-episode schizophrenia: 9-year outcomes of a randomised clinical trial. The British Journal of Psychiatry : the Journal of Mental Science. 199: 281-8. PMID 21292928 DOI: 10.1192/Bjp.Bp.110.081471 |
0.465 |
|
| 2011 |
Wessels AM, Bies RR, Pollock BG, Schneider LS, Lieberman JA, Stroup S, Li CH, Coley K, Kirshner MM, Marder SR. Population pharmacokinetic modeling of ziprasidone in patients with schizophrenia from the CATIE study. Journal of Clinical Pharmacology. 51: 1587-91. PMID 21209243 DOI: 10.1177/0091270010387604 |
0.475 |
|
| 2011 |
Stauffer VL, Case M, Kinon BJ, Conley R, Ascher-Svanum H, Kollack-Walker S, Kane J, McEvoy J, Lieberman J. Early response to antipsychotic therapy as a clinical marker of subsequent response in the treatment of patients with first-episode psychosis. Psychiatry Research. 187: 42-8. PMID 21168920 DOI: 10.1016/J.Psychres.2010.11.017 |
0.42 |
|
| 2011 |
Buchanan RW, Keefe RS, Lieberman JA, Barch DM, Csernansky JG, Goff DC, Gold JM, Green MF, Jarskog LF, Javitt DC, Kimhy D, Kraus MS, McEvoy JP, Mesholam-Gately RI, Seidman LJ, et al. A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia. Biological Psychiatry. 69: 442-9. PMID 21145041 DOI: 10.1016/J.Biopsych.2010.09.052 |
0.447 |
|
| 2011 |
McClay JL, Adkins DE, Aberg K, Bukszár J, Khachane AN, Keefe RS, Perkins DO, McEvoy JP, Stroup TS, Vann RE, Beardsley PM, Lieberman JA, Sullivan PF, van den Oord EJ. Genome-wide pharmacogenomic study of neurocognition as an indicator of antipsychotic treatment response in schizophrenia. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 36: 616-26. PMID 21107309 DOI: 10.1038/Npp.2010.193 |
0.648 |
|
| 2011 |
Girgis RR, Merrill DB, Vorel SR, Edward Kim, Kimberly Portland, You M, Pikalov A, Whitehead R, Lieberman JA. Aripiprazole versus haloperidol treatment in early-stage schizophrenia. Journal of Psychiatric Research. 45: 756-62. PMID 20937506 DOI: 10.1016/J.Jpsychires.2010.09.003 |
0.469 |
|
| 2011 |
Addington DE, Mohamed S, Rosenheck RA, Davis SM, Stroup TS, McEvoy JP, Swartz MS, Lieberman JA. Impact of second-generation antipsychotics and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia. The Journal of Clinical Psychiatry. 72: 75-80. PMID 20868641 DOI: 10.4088/Jcp.09M05258Gre |
0.686 |
|
| 2011 |
Caroff SN, Davis VG, Miller DD, Davis SM, Rosenheck RA, McEvoy JP, Campbell EC, Saltz BL, Riggio S, Chakos MH, Swartz MS, Keefe RS, Stroup TS, Lieberman JA. Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia. The Journal of Clinical Psychiatry. 72: 295-303. PMID 20816031 DOI: 10.4088/Jcp.09M05793Yel |
0.686 |
|
| 2011 |
Souza RP, Rosa DV, Romano-Silva MA, Zhen M, Meltzer HY, Lieberman JA, Remington G, Kennedy JL, Wong AH. Lack of association of NALCN genetic variants with schizophrenia. Psychiatry Research. 185: 450-2. PMID 20674038 DOI: 10.1016/J.Psychres.2010.07.009 |
0.494 |
|
| 2011 |
Rosenfeld AJ, Lieberman JA, Jarskog LF. Oxytocin, dopamine, and the amygdala: a neurofunctional model of social cognitive deficits in schizophrenia. Schizophrenia Bulletin. 37: 1077-87. PMID 20308198 DOI: 10.1093/Schbul/Sbq015 |
0.382 |
|
| 2011 |
Adkins DE, Aberg K, McClay JL, Bukszár J, Zhao Z, Jia P, Stroup TS, Perkins D, McEvoy JP, Lieberman JA, Sullivan PF, van den Oord EJ. Genomewide pharmacogenomic study of metabolic side effects to antipsychotic drugs. Molecular Psychiatry. 16: 321-32. PMID 20195266 DOI: 10.1038/Mp.2010.14 |
0.619 |
|
| 2011 |
McClay JL, Adkins DE, Aberg K, Stroup S, Perkins DO, Vladimirov VI, Lieberman JA, Sullivan PF, van den Oord EJ. Genome-wide pharmacogenomic analysis of response to treatment with antipsychotics. Molecular Psychiatry. 16: 76-85. PMID 19721433 DOI: 10.1038/Mp.2009.89 |
0.372 |
|
| 2011 |
Lyon GJ, Abi-Dargham A, Moore H, Lieberman JA, Javitch JA, Sulzer D. Presynaptic regulation of dopamine transmission in schizophrenia. Schizophrenia Bulletin. 37: 108-17. PMID 19525353 DOI: 10.1093/Schbul/Sbp010 |
0.468 |
|
| 2011 |
Lieberman JA. Interview: In search of the pathophysiology and prevention of schizophrenia Neuropsychiatry. 1: 225-231. DOI: 10.2217/NPY.11.30 |
0.408 |
|
| 2011 |
Davis SM, Stroup TS, Koch GG, Davis CE, Rosenheck RA, Lieberman JA. Time to all-cause treatment discontinuation as the primary outcome in the clinical antipsychotic trials of intervention effectiveness (CATIE) schizophrenia study Statistics in Biopharmaceutical Research. 3: 253-265. DOI: 10.1198/sbr.2011.10013 |
0.564 |
|
| 2011 |
Ballon JS, Girgis RR, Lieberman JA. Personalized Medicine for Schizophrenia Integrative Neuroscience and Personalized Medicine. DOI: 10.1093/acprof:oso/9780195393804.003.0006 |
0.416 |
|
| 2011 |
Walsh BT, Roose S, Lieberman JA. Alexander H Glassman Neuropsychopharmacology. 36: 2791-2791. DOI: 10.1038/Npp.2011.231 |
0.304 |
|
| 2011 |
Dunbar G, Hosford D, Segreti A, Lieberman J. P.3.e.017 Effects of alpha7 nicotinic receptor agonist TC-5619 in cognitive dysfunction in schizophrenia European Neuropsychopharmacology. 21. DOI: 10.1016/S0924-977X(11)70849-5 |
0.376 |
|
| 2011 |
Geddes JR, Stroup TS, Lieberman JA. Comparative Efficacy and Effectiveness in the Drug Treatment of Schizophrenia Schizophrenia: Third Edition. 525-539. DOI: 10.1002/9781444327298.ch25 |
0.663 |
|
| 2010 |
Sicard MN, Zai CC, Tiwari AK, Souza RP, Meltzer HY, Lieberman JA, Kennedy JL, Müller DJ. Polymorphisms of the HTR2C gene and antipsychotic-induced weight gain: an update and meta-analysis. Pharmacogenomics. 11: 1561-71. PMID 21121776 DOI: 10.2217/Pgs.10.123 |
0.343 |
|
| 2010 |
Wessels AM, Pollock BG, Anyama NG, Schneider LS, Lieberman JA, Marder SR, Bies RR. Association of 9-hydroxy risperidone concentrations with risk of switching or discontinuation in the clinical antipsychotic trial of intervention effectiveness-Alzheimer's disease trial. Journal of Clinical Psychopharmacology. 30: 683-7. PMID 21105282 DOI: 10.1097/Jcp.0B013E3181Fa05Bb |
0.345 |
|
| 2010 |
Souza RP, Meltzer HY, Lieberman JA, Le Foll B, Kennedy JL. Influence of neurexin 1 (NRXN1) polymorphisms in clozapine response. Human Psychopharmacology. 25: 582-5. PMID 20860064 DOI: 10.1002/Hup.1146 |
0.491 |
|
| 2010 |
Tiwari AK, Rodgers JB, Sicard M, Zai CC, Likhodi O, Freeman N, Meltzer HY, Lieberman JA, Kennedy JL, Müller DJ. Association study of polymorphisms in cholecystokinin gene and its receptors with antipsychotic induced weight gain in schizophrenia patients. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 34: 1484-90. PMID 20732371 DOI: 10.1016/J.Pnpbp.2010.08.009 |
0.32 |
|
| 2010 |
Huang J, Perlis RH, Lee PH, Rush AJ, Fava M, Sachs GS, Lieberman J, Hamilton SP, Sullivan P, Sklar P, Purcell S, Smoller JW. Cross-disorder genomewide analysis of schizophrenia, bipolar disorder, and depression. The American Journal of Psychiatry. 167: 1254-63. PMID 20713499 DOI: 10.1176/Appi.Ajp.2010.09091335 |
0.367 |
|
| 2010 |
Smith T, Weston C, Lieberman J. Schizophrenia (maintenance treatment). American Family Physician. 82: 338-9. PMID 20704164 |
0.427 |
|
| 2010 |
Zai CC, Manchia M, De Luca V, Tiwari AK, Squassina A, Zai GC, Strauss J, Shaikh SA, Freeman N, Meltzer HY, Lieberman J, Le Foll B, Kennedy JL. Association study of BDNF and DRD3 genes in schizophrenia diagnosis using matched case-control and family based study designs. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 34: 1412-8. PMID 20667458 DOI: 10.1016/J.Pnpbp.2010.07.019 |
0.383 |
|
| 2010 |
Souza RP, Remington G, Chowdhury NI, Lau MK, Voineskos AN, Lieberman JA, Meltzer HY, Kennedy JL. Association study of the GSK-3B gene with tardive dyskinesia in European Caucasians. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 20: 688-94. PMID 20605420 DOI: 10.1016/J.Euroneuro.2010.05.002 |
0.348 |
|
| 2010 |
Zai CC, Tiwari AK, Müller DJ, De Luca V, Shinkai T, Shaikh S, Ni X, Sibony D, Voineskos AN, Meltzer HY, Lieberman JA, Potkin SG, Remington G, Kennedy JL. The catechol-O-methyl-transferase gene in tardive dyskinesia. The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry. 11: 803-12. PMID 20586531 DOI: 10.3109/15622975.2010.486043 |
0.348 |
|
| 2010 |
Karam CS, Ballon JS, Bivens NM, Freyberg Z, Girgis RR, Lizardi-Ortiz JE, Markx S, Lieberman JA, Javitch JA. Signaling pathways in schizophrenia: emerging targets and therapeutic strategies. Trends in Pharmacological Sciences. 31: 381-90. PMID 20579747 DOI: 10.1016/J.Tips.2010.05.004 |
0.414 |
|
| 2010 |
El-Sayed M, Steen RG, Poe MD, Bethea TC, Gerig G, Lieberman J, Sikich L. Brain volumes in psychotic youth with schizophrenia and mood disorders. Journal of Psychiatry & Neuroscience : Jpn. 35: 229-36. PMID 20569649 DOI: 10.1503/Jpn.090051 |
0.424 |
|
| 2010 |
Gilmore JH, Kang C, Evans DD, Wolfe HM, Smith JK, Lieberman JA, Lin W, Hamer RM, Styner M, Gerig G. Prenatal and neonatal brain structure and white matter maturation in children at high risk for schizophrenia. The American Journal of Psychiatry. 167: 1083-91. PMID 20516153 DOI: 10.1176/Appi.Ajp.2010.09101492 |
0.444 |
|
| 2010 |
Findling RL, Johnson JL, McClellan J, Frazier JA, Vitiello B, Hamer RM, Lieberman JA, Ritz L, McNamara NK, Lingler J, Hlastala S, Pierson L, Puglia M, Maloney AE, Kaufman EM, et al. Double-blind maintenance safety and effectiveness findings from the Treatment of Early-Onset Schizophrenia Spectrum (TEOSS) study. Journal of the American Academy of Child and Adolescent Psychiatry. 49: 583-94; quiz 632. PMID 20494268 DOI: 10.1016/J.Jaac.2010.03.013 |
0.486 |
|
| 2010 |
Konneker TI, Crowley JJ, Quackenbush CR, Keefe RS, Perkins DO, Stroup TS, Lieberman JA, van den Oord E, Sullivan PF. No association of the serotonin transporter polymorphisms 5-HTTLPR and RS25531 with schizophrenia or neurocognition. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics. 153: 1115-7. PMID 20468059 DOI: 10.1002/Ajmg.B.31077 |
0.644 |
|
| 2010 |
Souza RP, Remington G, Meltzer HY, Lieberman JA, Kennedy JL, Wong AH. Phosphodiesterase 4B genetic variants are not associated with antipsychotic-induced tardive dyskinesia. International Clinical Psychopharmacology. 25: 264-9. PMID 20436352 DOI: 10.1016/J.Schres.2010.02.586 |
0.441 |
|
| 2010 |
Tiwari AK, Zai CC, Meltzer HY, Lieberman JA, Müller DJ, Kennedy JL. Association study of polymorphisms in insulin induced gene 2 (INSIG2) with antipsychotic-induced weight gain in European and African-American schizophrenia patients. Human Psychopharmacology. 25: 253-9. PMID 20373477 DOI: 10.1002/Hup.1111 |
0.39 |
|
| 2010 |
Souza RP, de Luca V, Remington G, Lieberman JA, Meltzer HY, Kennedy JL, Wong AH. Glial cell line-derived neurotrophic factor receptor alpha 2 (GFRA2) gene is associated with tardive dyskinesia. Psychopharmacology. 210: 347-54. PMID 20369355 DOI: 10.1007/S00213-010-1829-4 |
0.329 |
|
| 2010 |
Hooper SR, Giuliano AJ, Youngstrom EA, Breiger D, Sikich L, Frazier JA, Findling RL, McClellan J, Hamer RM, Vitiello B, Lieberman JA. Neurocognition in early-onset schizophrenia and schizoaffective disorders. Journal of the American Academy of Child and Adolescent Psychiatry. 49: 52-60. PMID 20215926 DOI: 10.1016/J.Jaac.2009.11.001 |
0.434 |
|
| 2010 |
Souza RP, de Luca V, Meltzer HY, Lieberman JA, Kennedy JL. Schizophrenia severity and clozapine treatment outcome association with oxytocinergic genes. The International Journal of Neuropsychopharmacology / Official Scientific Journal of the Collegium Internationale Neuropsychopharmacologicum (Cinp). 13: 793-8. PMID 20196918 DOI: 10.1017/S1461145710000167 |
0.494 |
|
| 2010 |
Souza RP, de Luca V, Meltzer HY, Lieberman JA, Kennedy JL. Influence of serotonin 3A and 3B receptor genes on clozapine treatment response in schizophrenia. Pharmacogenetics and Genomics. 20: 274-6. PMID 20168265 DOI: 10.1097/Fpc.0B013E328337Ce3E |
0.333 |
|
| 2010 |
Souza RP, Romano-Silva MA, Lieberman JA, Meltzer HY, MacNeil LT, Culotti JG, Kennedy JL, Wong AH. Genetic association of the GDNF alpha-receptor genes with schizophrenia and clozapine response. Journal of Psychiatric Research. 44: 700-6. PMID 20116071 DOI: 10.1016/J.Jpsychires.2010.01.002 |
0.491 |
|
| 2010 |
Tiwari AK, Zai CC, Likhodi O, Lisker A, Singh D, Souza RP, Batra P, Zaidi SH, Chen S, Liu F, Puls I, Meltzer HY, Lieberman JA, Kennedy JL, Müller DJ. A common polymorphism in the cannabinoid receptor 1 (CNR1) gene is associated with antipsychotic-induced weight gain in Schizophrenia. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 35: 1315-24. PMID 20107430 DOI: 10.1038/Npp.2009.235 |
0.423 |
|
| 2010 |
Glantz LA, Gilmore JH, Overstreet DH, Salimi K, Lieberman JA, Jarskog LF. Pro-apoptotic Par-4 and dopamine D2 receptor in temporal cortex in schizophrenia, bipolar disorder and major depression. Schizophrenia Research. 118: 292-9. PMID 20067857 DOI: 10.1016/J.Schres.2009.12.027 |
0.462 |
|
| 2010 |
Novak G, Gallo A, Zai CC, Meltzer HY, Lieberman JA, Potkin SG, Voineskos AN, Remington G, Kennedy JL, Levesque D, Le Foll B. Association of the orphan nuclear receptor NR4A1 with tardive dyskinesia. Psychiatric Genetics. 20: 39-43. PMID 20010315 DOI: 10.1097/Ypg.0B013E3283351221 |
0.337 |
|
| 2010 |
Hirata Y, Souza RP, Lieberman JA, Meltzer HY, Kennedy JL. Lack of association between HTR4 gene polymorphisms and schizophrenia in case-control and family-based samples. Psychiatry Research. 175: 176-8. PMID 19892407 DOI: 10.1016/J.Psychres.2009.08.005 |
0.402 |
|
| 2010 |
Aberg K, Adkins DE, Bukszár J, Webb BT, Caroff SN, Miller DD, Sebat J, Stroup S, Fanous AH, Vladimirov VI, McClay JL, Lieberman JA, Sullivan PF, van den Oord EJ. Genomewide association study of movement-related adverse antipsychotic effects. Biological Psychiatry. 67: 279-82. PMID 19875103 DOI: 10.1016/J.Biopsych.2009.08.036 |
0.41 |
|
| 2010 |
Perlick DA, Rosenheck RA, Kaczynski R, Swartz MS, Canive JM, Lieberman JA. Impact of antipsychotic medication on family burden in schizophrenia: longitudinal results of CATIE trial. Schizophrenia Research. 116: 118-25. PMID 19864114 DOI: 10.1016/J.Schres.2009.09.026 |
0.449 |
|
| 2010 |
Jin Y, Pollock BG, Coley K, Miller D, Marder SR, Florian J, Schneider L, Lieberman J, Kirshner M, Bies RR. Population pharmacokinetics of perphenazine in schizophrenia patients from CATIE: impact of race and smoking. Journal of Clinical Pharmacology. 50: 73-80. PMID 19843655 DOI: 10.1177/0091270009343694 |
0.304 |
|
| 2010 |
Zai CC, Tiwari AK, Basile V, de Luca V, Müller DJ, Voineskos AN, Remington G, Meltzer HY, Lieberman JA, Potkin SG, Kennedy JL. Oxidative stress in tardive dyskinesia: genetic association study and meta-analysis of NADPH quinine oxidoreductase 1 (NQO1) and Superoxide dismutase 2 (SOD2, MnSOD) genes. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 34: 50-6. PMID 19778569 DOI: 10.1016/J.Pnpbp.2009.09.020 |
0.412 |
|
| 2010 |
Tsai HT, Caroff SN, Miller DD, McEvoy J, Lieberman JA, North KE, Stroup TS, Sullivan PF. A candidate gene study of Tardive dyskinesia in the CATIE schizophrenia trial. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics. 153: 336-40. PMID 19475583 DOI: 10.1002/Ajmg.B.30981 |
0.659 |
|
| 2010 |
Ballon JS, Lieberman JA. Advances in the Management of Treatment- Resistant Schizophrenia Focus. 8: 475-487. DOI: 10.1176/FOC.8.4.FOC475 |
0.33 |
|
| 2010 |
Rosenheck RA, Scott Stroup T, Lieberman JA. Conclusion and implications for practice and policy Antipsychotic Trials in Schizophrenia: the Catie Project. 288-306. DOI: 10.1017/CBO9780511712265.018 |
0.327 |
|
| 2010 |
Scott Stroup T, McEvoy JP, Lieberman JA. Study design and protocol development process Antipsychotic Trials in Schizophrenia: the Catie Project. 1-21. DOI: 10.1017/CBO9780511712265.002 |
0.33 |
|
| 2010 |
Scott Stroup T, Lieberman JA. Antipsychotic trials in schizophrenia: The CATIE project Antipsychotic Trials in Schizophrenia: the Catie Project. 1-312. DOI: 10.1017/CBO9780511712265 |
0.408 |
|
| 2010 |
Buchanan RW, Barch D, Csernansky J, Goff D, Gold J, Jarskog F, Javitt D, Keefe R, Lieberman J, McEvoy J, McMahon R, Marder S. MK-0777 FOR THE TREATMENT OF COGNITIVE IMPAIRMENTS IN PEOPLE WITH SCHIZOPHRENIA Schizophrenia Research. 117: 119. DOI: 10.1016/J.Schres.2010.02.053 |
0.449 |
|
| 2009 |
Souza RP, Tampakeras M, Basile V, Shinkai T, Rosa DV, Potkin S, Meltzer HY, Lieberman JA, Romano-Silva MA, Kennedy JL. Lack of association of GPX1 and MnSOD genes with symptom severity and response to clozapine treatment in schizophrenia subjects. Human Psychopharmacology. 24: 676-9. PMID 19946932 DOI: 10.1002/Hup.1076 |
0.461 |
|
| 2009 |
McCarthy SE, Makarov V, Kirov G, Addington AM, McClellan J, Yoon S, Perkins DO, Dickel DE, Kusenda M, Krastoshevsky O, Krause V, Kumar RA, Grozeva D, Malhotra D, Walsh T, ... ... Lieberman JA, et al. Microduplications of 16p11.2 are associated with schizophrenia. Nature Genetics. 41: 1223-7. PMID 19855392 DOI: 10.1038/Ng.474 |
0.637 |
|
| 2009 |
Penn DL, Keefe RS, Davis SM, Meyer PS, Perkins DO, Losardo D, Lieberman JA. The effects of antipsychotic medications on emotion perception in patients with chronic schizophrenia in the CATIE trial. Schizophrenia Research. 115: 17-23. PMID 19766459 DOI: 10.1016/J.Schres.2009.08.016 |
0.357 |
|
| 2009 |
Salimi K, Jarskog LF, Lieberman JA. Antipsychotic drugs for first-episode schizophrenia: a comparative review. Cns Drugs. 23: 837-55. PMID 19739694 DOI: 10.2165/11314280-000000000-00000 |
0.508 |
|
| 2009 |
Zai CC, Tiwari AK, King N, De Luca V, Mueller DJ, Shaikh S, Wong GW, Meltzer HY, Lieberman JA, Kennedy JL. Association study of the gamma-aminobutyric acid type a receptor gamma2 subunit gene with schizophrenia. Schizophrenia Research. 114: 33-8. PMID 19682861 DOI: 10.1016/J.Schres.2009.07.010 |
0.428 |
|
| 2009 |
Meyer JM, McEvoy JP, Davis VG, Goff DC, Nasrallah HA, Davis SM, Hsiao JK, Swartz MS, Stroup TS, Lieberman JA. Inflammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the clinical antipsychotic trials of intervention effectiveness study. Biological Psychiatry. 66: 1013-22. PMID 19640511 DOI: 10.1016/J.Biopsych.2009.06.005 |
0.636 |
|
| 2009 |
Rosenheck RA, Davis VG, Davis SM, Stroup S, McEvoy J, Swartz M, Lieberman J. Can a nonequivalent choice of dosing regimen bias the results of flexible dose double blind trials? The CATIE schizophrenia trial. Schizophrenia Research. 113: 12-8. PMID 19545976 DOI: 10.1016/J.Schres.2009.06.002 |
0.372 |
|
| 2009 |
Smith TE, Weston CA, Lieberman JA. Schizophrenia (maintenance treatment). Bmj Clinical Evidence. 2009. PMID 19445748 |
0.367 |
|
| 2009 |
Patel JK, Buckley PF, Woolson S, Hamer RM, McEvoy JP, Perkins DO, Lieberman JA. Metabolic profiles of second-generation antipsychotics in early psychosis: findings from the CAFE study. Schizophrenia Research. 111: 9-16. PMID 19398192 DOI: 10.1016/J.Schres.2009.03.025 |
0.343 |
|
| 2009 |
Marx CE, Keefe RS, Buchanan RW, Hamer RM, Kilts JD, Bradford DW, Strauss JL, Naylor JC, Payne VM, Lieberman JA, Savitz AJ, Leimone LA, Dunn L, Porcu P, Morrow AL, et al. Proof-of-concept trial with the neurosteroid pregnenolone targeting cognitive and negative symptoms in schizophrenia. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 34: 1885-903. PMID 19339966 DOI: 10.1038/Npp.2009.26 |
0.42 |
|
| 2009 |
Reaven GM, Lieberman JA, Sethuraman G, Kraemer H, Davis JM, Blasey C, Tsuang MT, Schatzberg AF. In search of moderators and mediators of hyperglycemia with atypical antipsychotic treatment. Journal of Psychiatric Research. 43: 997-1002. PMID 19268968 DOI: 10.1016/J.Jpsychires.2009.01.010 |
0.32 |
|
| 2009 |
Zai CC, Tiwari AK, De Luca V, Müller DJ, Bulgin N, Hwang R, Zai GC, King N, Voineskos AN, Meltzer HY, Lieberman JA, Potkin SG, Remington G, Kennedy JL. Genetic study of BDNF, DRD3, and their interaction in tardive dyskinesia. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 19: 317-28. PMID 19217756 DOI: 10.1016/J.Euroneuro.2009.01.001 |
0.337 |
|
| 2009 |
Chwastiak LA, Rosenheck RA, McEvoy JP, Stroup TS, Swartz MS, Davis SM, Lieberman JA. The impact of obesity on health care costs among persons with schizophrenia. General Hospital Psychiatry. 31: 1-7. PMID 19134502 DOI: 10.1016/J.Genhosppsych.2008.09.012 |
0.636 |
|
| 2009 |
Stroup TS, Lieberman JA, McEvoy JP, Davis SM, Swartz MS, Keefe RS, Miller AL, Rosenheck RA, Hsiao JK. Results of phase 3 of the CATIE schizophrenia trial. Schizophrenia Research. 107: 1-12. PMID 19027269 DOI: 10.1016/J.Schres.2008.10.011 |
0.693 |
|
| 2009 |
Kleinman L, Lieberman J, Dube S, Mohs R, Zhao Y, Kinon B, Carpenter W, Harvey PD, Green MF, Keefe RS, Frank L, Bowman L, Revicki DA. Development and psychometric performance of the schizophrenia objective functioning instrument: an interviewer administered measure of function. Schizophrenia Research. 107: 275-85. PMID 19013769 DOI: 10.1016/J.Schres.2008.10.002 |
0.384 |
|
| 2009 |
Lieberman JA, Papadakis K, Csernansky J, Litman R, Volavka J, Jia XD, Gage A. A randomized, placebo-controlled study of memantine as adjunctive treatment in patients with schizophrenia Neuropsychopharmacology. 34: 1322-1329. PMID 19005465 DOI: 10.1038/Npp.2008.200 |
0.514 |
|
| 2009 |
van den Oord EJ, Adkins DE, McClay J, Lieberman J, Sullivan PF. A systematic method for estimating individual responses to treatment with antipsychotics in CATIE. Schizophrenia Research. 107: 13-21. PMID 18930379 DOI: 10.1016/J.Schres.2008.09.009 |
0.359 |
|
| 2009 |
Thompson PM, Bartzokis G, Hayashi KM, Klunder AD, Lu PH, Edwards N, Hong MS, Yu M, Geaga JA, Toga AW, Charles C, Perkins DO, McEvoy J, Hamer RM, Tohen M, ... ... Lieberman JA, et al. Time-lapse mapping of cortical changes in schizophrenia with different treatments. Cerebral Cortex (New York, N.Y. : 1991). 19: 1107-23. PMID 18842668 DOI: 10.1093/Cercor/Bhn152 |
0.445 |
|
| 2009 |
Mohamed S, Rosenheck R, McEvoy J, Swartz M, Stroup S, Lieberman JA. Cross-sectional and longitudinal relationships between insight and attitudes toward medication and clinical outcomes in chronic schizophrenia. Schizophrenia Bulletin. 35: 336-46. PMID 18586692 DOI: 10.1093/Schbul/Sbn067 |
0.35 |
|
| 2009 |
Pinheiro AP, Keefe RSE, Skelly T, Olarte M, Leviel K, Lange LA, Lange EM, Stroup TS, Lieberman J, Sullivan PF. Erratum: Rates of depressive and anxiety disorders in a residential mother-infant unit for unsettled infants (Australian and New Zealand Journal of Psychiatry (2007) 41 (836-842)) Australian and New Zealand Journal of Psychiatry. 43. DOI: 10.1080/00048670903270266 |
0.454 |
|
| 2009 |
Pinheiro AP, Keefe RSE, Skelly T, Olarte M, Leviel K, Lange LA, Lange EM, Stroup TS, Lieberman J, Sullivan Pf. Erratum: AKT1 and neurocognition in schizophrenia (Australian and New Zealand Journal of Psychiatry (2007) 41 (169-177)) Australian and New Zealand Journal of Psychiatry. 43. DOI: 10.1080/00048670903228991 |
0.652 |
|
| 2009 |
Sullivan PF, Lin D, Tzeng J, van den Oord E, Perkins D, Stroup TS, Wagner M, Lee S, Wright FA, Zou F, Liu W, Downing AM, Lieberman J, Close SL. Erratum: Genomewide association for schizophrenia in the CATIE study: results of stage 1 Molecular Psychiatry. 14: 1144-1144. DOI: 10.1038/Mp.2008.74 |
0.652 |
|
| 2008 |
Morey RA, Mitchell TV, Inan S, Lieberman JA, Belger A. Neural correlates of automatic and controlled auditory processing in schizophrenia. The Journal of Neuropsychiatry and Clinical Neurosciences. 20: 419-30. PMID 19196926 DOI: 10.1176/Appi.Neuropsych.20.4.419 |
0.428 |
|
| 2008 |
Rosenheck RA, Davis S, Covell N, Essock S, Swartz M, Stroup S, McEvoy J, Lieberman J. Does switching to a new antipsychotic improve outcomes? Data from the CATIE Trial. Schizophrenia Research. 107: 22-9. PMID 18993031 DOI: 10.1016/J.Schres.2008.09.031 |
0.323 |
|
| 2008 |
Lieberman JA, Bymaster FP, Meltzer HY, Deutch AY, Duncan GE, Marx CE, Aprille JR, Dwyer DS, Li XM, Mahadik SP, Duman RS, Porter JH, Modica-Napolitano JS, Newton SS, Csernansky JG. Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection. Pharmacological Reviews. 60: 358-403. PMID 18922967 DOI: 10.1124/Pr.107.00107 |
0.488 |
|
| 2008 |
Zai CC, Romano-Silva MA, Hwang R, Zai GC, Deluca V, Müller DJ, King N, Voineskos AN, Meltzer HY, Lieberman JA, Potkin SG, Remington G, Kennedy JL. Genetic study of eight AKT1 gene polymorphisms and their interaction with DRD2 gene polymorphisms in tardive dyskinesia. Schizophrenia Research. 106: 248-52. PMID 18838251 DOI: 10.1016/J.Schres.2008.08.036 |
0.379 |
|
| 2008 |
Miller DD, Caroff SN, Davis SM, Rosenheck RA, McEvoy JP, Saltz BL, Riggio S, Chakos MH, Swartz MS, Keefe RS, Stroup TS, Lieberman JA. Extrapyramidal side-effects of antipsychotics in a randomised trial. The British Journal of Psychiatry : the Journal of Mental Science. 193: 279-88. PMID 18827289 DOI: 10.1192/Bjp.Bp.108.050088 |
0.625 |
|
| 2008 |
Sikich L, Frazier JA, McClellan J, Findling RL, Vitiello B, Ritz L, Ambler D, Puglia M, Maloney AE, Michael E, De Jong S, Slifka K, Noyes N, Hlastala S, Pierson L, ... Lieberman JA, et al. Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. The American Journal of Psychiatry. 165: 1420-31. PMID 18794207 DOI: 10.1176/Appi.Ajp.2008.08050756 |
0.507 |
|
| 2008 |
Daumit GL, Goff DC, Meyer JM, Davis VG, Nasrallah HA, McEvoy JP, Rosenheck R, Davis SM, Hsiao JK, Stroup TS, Lieberman JA. Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study. Schizophrenia Research. 105: 175-87. PMID 18775645 DOI: 10.1016/J.Schres.2008.07.006 |
0.631 |
|
| 2008 |
Swanson JW, Swartz MS, Van Dorn RA, Volavka J, Monahan J, Stroup TS, McEvoy JP, Wagner HR, Elbogen EB, Lieberman JA. Comparison of antipsychotic medication effects on reducing violence in people with schizophrenia. The British Journal of Psychiatry : the Journal of Mental Science. 193: 37-43. PMID 18700216 DOI: 10.1192/Bjp.Bp.107.042630 |
0.702 |
|
| 2008 |
Lieberman JA, Javitch JA, Moore H. Cholinergic agonists as novel treatments for schizophrenia: the promise of rational drug development for psychiatry. The American Journal of Psychiatry. 165: 931-6. PMID 18676593 DOI: 10.1176/Appi.Ajp.2008.08050769 |
0.492 |
|
| 2008 |
Kinon BJ, Volavka J, Stauffer V, Edwards SE, Liu-Seifert H, Chen L, Adams DH, Lindenmayer JP, McEvoy JP, Buckley PF, Lieberman JA, Meltzer HY, Wilson DR, Citrome L. Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, fixed-dose study. Journal of Clinical Psychopharmacology. 28: 392-400. PMID 18626265 DOI: 10.1097/Jcp.0B013E31817E63A5 |
0.353 |
|
| 2008 |
Meyer JM, Davis VG, McEvoy JP, Goff DC, Nasrallah HA, Davis SM, Daumit GL, Hsiao J, Swartz MS, Stroup TS, Lieberman JA. Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1. Schizophrenia Research. 103: 104-9. PMID 18534821 DOI: 10.1016/J.Schres.2008.04.023 |
0.693 |
|
| 2008 |
Sultzer DL, Davis SM, Tariot PN, Dagerman KS, Lebowitz BD, Lyketsos CG, Rosenheck RA, Hsiao JK, Lieberman JA, Schneider LS. Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trial. The American Journal of Psychiatry. 165: 844-54. PMID 18519523 DOI: 10.1176/Appi.Ajp.2008.07111779 |
0.351 |
|
| 2008 |
Souza RP, Romano-Silva MA, Lieberman JA, Meltzer HY, Wong AH, Kennedy JL. Association study of GSK3 gene polymorphisms with schizophrenia and clozapine response. Psychopharmacology. 200: 177-86. PMID 18500637 DOI: 10.1007/S00213-008-1193-9 |
0.522 |
|
| 2008 |
Swartz MS, Stroup TS, McEvoy JP, Davis SM, Rosenheck RA, Keefe RS, Hsiao JK, Lieberman JA. What CATIE found: results from the schizophrenia trial. Psychiatric Services (Washington, D.C.). 59: 500-6. PMID 18451005 DOI: 10.1176/Ps.2008.59.5.500 |
0.659 |
|
| 2008 |
Lieberman JA, Drake RE, Sederer LI, Belger A, Keefe R, Perkins D, Stroup S. Science and recovery in schizophrenia. Psychiatric Services (Washington, D.C.). 59: 487-96. PMID 18451003 DOI: 10.1176/Ps.2008.59.5.487 |
0.462 |
|
| 2008 |
Mohamed S, Rosenheck R, Swartz M, Stroup S, Lieberman JA, Keefe RS. Relationship of cognition and psychopathology to functional impairment in schizophrenia. The American Journal of Psychiatry. 165: 978-87. PMID 18450928 DOI: 10.1176/Appi.Ajp.2008.07111713 |
0.438 |
|
| 2008 |
Girgis RR, Javitch JA, Lieberman JA. Antipsychotic drug mechanisms: links between therapeutic effects, metabolic side effects and the insulin signaling pathway. Molecular Psychiatry. 13: 918-29. PMID 18414407 DOI: 10.1038/Mp.2008.40 |
0.323 |
|
| 2008 |
Fleischhacker WW, Cetkovich-Bakmas M, De Hert M, Hennekens CH, Lambert M, Leucht S, Maj M, McIntyre RS, Naber D, Newcomer JW, Olfson M, Osby U, Sartorius N, Lieberman JA. Comorbid somatic illnesses in patients with severe mental disorders: clinical, policy, and research challenges. The Journal of Clinical Psychiatry. 69: 514-9. PMID 18370570 DOI: 10.4088/Jcp.V69N0401 |
0.324 |
|
| 2008 |
Sullivan PF, Lin D, Tzeng JY, van den Oord E, Perkins D, Stroup TS, Wagner M, Lee S, Wright FA, Zou F, Liu W, Downing AM, Lieberman J, Close SL. Genomewide association for schizophrenia in the CATIE study: results of stage 1. Molecular Psychiatry. 13: 570-84. PMID 18347602 DOI: 10.1038/Mp.2008.25 |
0.64 |
|
| 2008 |
Perkins DO, Gu H, Weiden PJ, McEvoy JP, Hamer RM, Lieberman JA. Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study. The Journal of Clinical Psychiatry. 69: 106-13. PMID 18312044 DOI: 10.4088/Jcp.V69N0114 |
0.419 |
|
| 2008 |
Lewis S, Lieberman J. CATIE and CUtLASS: can we handle the truth? British Journal of Psychiatry. 192: 161-163. PMID 18310570 DOI: 10.1192/Bjp.Bp.107.037218 |
0.397 |
|
| 2008 |
Crowley JJ, Keefe RS, Perkins DO, Stroup TS, Lieberman JA, Sullivan PF. The neuregulin 1 promoter polymorphism rs6994992 is not associated with chronic schizophrenia or neurocognition. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics. 147: 1298-300. PMID 18286587 DOI: 10.1002/Ajmg.B.30727 |
0.66 |
|
| 2008 |
Hill SK, Sweeney JA, Hamer RM, Keefe RS, Perkins DO, Gu H, McEvoy JP, Lieberman JA. Efficiency of the CATIE and BACS neuropsychological batteries in assessing cognitive effects of antipsychotic treatments in schizophrenia. Journal of the International Neuropsychological Society : Jins. 14: 209-21. PMID 18282319 DOI: 10.1017/S1355617708080570 |
0.38 |
|
| 2008 |
Campbell DB, Lange LA, Skelly T, Lieberman J, Levitt P, Sullivan PF. Association of RGS2 and RGS5 variants with schizophrenia symptom severity. Schizophrenia Research. 101: 67-75. PMID 18262772 DOI: 10.1016/J.Schres.2008.01.006 |
0.501 |
|
| 2008 |
Meyer JM, Davis VG, Goff DC, McEvoy JP, Nasrallah HA, Davis SM, Rosenheck RA, Daumit GL, Hsiao J, Swartz MS, Stroup TS, Lieberman JA. Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1. Schizophrenia Research. 101: 273-86. PMID 18258416 DOI: 10.1016/J.Schres.2007.12.487 |
0.668 |
|
| 2008 |
Resnick SG, Rosenheck RA, Canive JM, De Souza C, Stroup TS, McEvoy J, Davis S, Keefe RS, Swartz M, Lieberman J. Employment outcomes in a randomized trial of second-generation antipsychotics and perphenazine in the treatment of individuals with schizophrenia. The Journal of Behavioral Health Services & Research. 35: 215-25. PMID 18246429 DOI: 10.1007/S11414-007-9101-3 |
0.662 |
|
| 2008 |
Swartz MS, Wagner HR, Swanson JW, Stroup TS, McEvoy JP, Reimherr F, Miller DD, McGee M, Khan A, Canive JM, Davis SM, Hsiao JK, Lieberman JA. The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: results from the CATIE study. Schizophrenia Research. 100: 39-52. PMID 18191383 DOI: 10.1016/J.Schres.2007.11.034 |
0.681 |
|
| 2008 |
Campbell DB, Ebert PJ, Skelly T, Stroup TS, Lieberman J, Levitt P, Sullivan PF. Ethnic Stratification of the Association of RGS4 Variants with Antipsychotic Treatment Response in Schizophrenia Biological Psychiatry. 63: 32-41. PMID 17588543 DOI: 10.1016/J.Biopsych.2007.04.018 |
0.703 |
|
| 2008 |
Sevy S, Robinson DG, Holloway S, Alvir JM, Woerner MG, Bilder R, Goldman R, Lieberman J, Kane J. Correlates of substance misuse in patients with first-episode schizophrenia and schizoaffective disorder Acta Psychiatrica Scandinavica. 104: 367-374. DOI: 10.1111/J.1600-0447.2001.00452.X |
0.486 |
|
| 2008 |
Girgis RR, Schobel SA, Lieberman JA. Biological treatments for psychotic disorders Essential Psychiatry, Fourth Edition. 586-621. DOI: 10.1017/CBO9780511544125.027 |
0.318 |
|
| 2008 |
Pedra Souza R, Romano-Silva MA, Lieberman JA, Meltzer HY, Culotti JG, Kennedy JL, Wong AH. GENETIC ASSOCIATION ANALYSIS OF THE GFR ALPHA GENES WITH SCHIZOPHRENIA AND CLOZAPINE RESPONSE Schizophrenia Research. 102: 190. DOI: 10.1016/S0920-9964(08)70577-2 |
0.429 |
|
| 2008 |
Stroup S, Lieberman J, McEvoy J, Swartz M, Davis S, Rosenheck R, Keefe R. Findings Of Phase 3 Of The Catie Schizophrenia Trial Schizophrenia Research. 102: 34-35. DOI: 10.1016/S0920-9964(08)70109-9 |
0.475 |
|
| 2008 |
Kennedy JL, Mueller D, Zai C, Desouza R, Tiwari A, Meltzer H, Lieberman J. PHARMACOGENETICS OF SCHIZOPHRENIA: TARDIVE DYSKINESIA AND WEIGHT GAIN Schizophrenia Research. 102: 34. DOI: 10.1016/S0920-9964(08)70107-5 |
0.37 |
|
| 2007 |
Renou J, De Luca V, Zai CC, Bulgin N, Remington G, Meltzer HY, Lieberman JA, Le Foll B, Kennedy JL. Multiple variants of the DRD3, but not BDNF gene, influence age-at-onset of schizophrenia. Molecular Psychiatry. 12: 1058-60. PMID 18043709 DOI: 10.1038/Sj.Mp.4002092 |
0.38 |
|
| 2007 |
Lieberman JA. Neuroprotection: a new strategy in the treatment of schizophrenia. Neurobiological basis of neurodegeneration and neuroprotection Cns Spectrums. 12: 4-6. PMID 17934388 |
0.398 |
|
| 2007 |
De Luca V, Müller DJ, Hwang R, Lieberman JA, Volavka J, Meltzer HY, Kennedy JL. HTR2C haplotypes and antipsychotics-induced weight gain: X-linked multimarker analysis. Human Psychopharmacology. 22: 463-7. PMID 17702092 DOI: 10.1002/Hup.868 |
0.311 |
|
| 2007 |
Frazier JA, McClellan J, Findling RL, Vitiello B, Anderson R, Zablotsky B, Williams E, McNamara NK, Jackson JA, Ritz L, Hlastala SA, Pierson L, Varley JA, Puglia M, Maloney AE, ... ... Lieberman JA, et al. Treatment of early-onset schizophrenia spectrum disorders (TEOSS): demographic and clinical characteristics. Journal of the American Academy of Child and Adolescent Psychiatry. 46: 979-88. PMID 17667477 DOI: 10.1097/Chi.0B013E31807083Fd |
0.493 |
|
| 2007 |
McClellan J, Sikich L, Findling RL, Frazier JA, Vitiello B, Hlastala SA, Williams E, Ambler D, Hunt-Harrison T, Maloney AE, Ritz L, Anderson R, Hamer RM, Lieberman JA. Treatment of early-onset schizophrenia spectrum disorders (TEOSS): rationale, design, and methods. Journal of the American Academy of Child and Adolescent Psychiatry. 46: 969-78. PMID 17667476 DOI: 10.1097/Chi.0B013E3180691779 |
0.49 |
|
| 2007 |
Buchanan RW, Freedman R, Javitt DC, Abi-Dargham A, Lieberman JA. Recent advances in the development of novel pharmacological agents for the treatment of cognitive impairments in schizophrenia. Schizophrenia Bulletin. 33: 1120-30. PMID 17641146 DOI: 10.1093/Schbul/Sbm083 |
0.444 |
|
| 2007 |
Keefe RS, Sweeney JA, Gu H, Hamer RM, Perkins DO, McEvoy JP, Lieberman JA. Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison. The American Journal of Psychiatry. 164: 1061-71. PMID 17606658 DOI: 10.1176/Ajp.2007.164.7.1061 |
0.425 |
|
| 2007 |
McEvoy JP, Lieberman JA, Perkins DO, Hamer RM, Gu H, Lazarus A, Sweitzer D, Olexy C, Weiden P, Strakowski SD. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. The American Journal of Psychiatry. 164: 1050-60. PMID 17606657 DOI: 10.1176/Ajp.2007.164.7.1050 |
0.372 |
|
| 2007 |
Keefe RS, Bilder RM, Davis SM, Harvey PD, Palmer BW, Gold JM, Meltzer HY, Green MF, Capuano G, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Davis CE, ... ... Lieberman JA, et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Archives of General Psychiatry. 64: 633-47. PMID 17548746 DOI: 10.1001/Archpsyc.64.6.633 |
0.674 |
|
| 2007 |
Pinheiro AP, Keefe RS, Skelly T, Olarte M, Leviel K, Lange LA, Lange EM, Stroup TS, Lieberman J, Sullivan PF. AKT1 and neurocognition in schizophrenia. The Australian and New Zealand Journal of Psychiatry. 41: 169-77. PMID 17464696 DOI: 10.1080/00048670601109956 |
0.706 |
|
| 2007 |
Newcomer JW, Lieberman JA. Comparing safety and tolerability of antipsychotic treatment The Journal of Clinical Psychiatry. 68. PMID 17388701 DOI: 10.4088/Jcp.0307E07 |
0.31 |
|
| 2007 |
Rosenheck RA, Lieberman JA. Cost-effectiveness measures, methods, and policy implications from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for schizophrenia The Journal of Clinical Psychiatry. 68. PMID 17335313 DOI: 10.4088/Jcp.0207E05 |
0.406 |
|
| 2007 |
Lieberman JA. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia: efficacy, safety and cost outcomes of CATIE and other trials The Journal of Clinical Psychiatry. 68. PMID 17335312 DOI: 10.4088/Jcp.0207E04 |
0.443 |
|
| 2007 |
Lieberman JA, Perkins DO, Jarskog LF. Neuroprotection: a therapeutic strategy to prevent deterioration associated with schizophrenia. Cns Spectrums. 12: 1-13; quiz 14. PMID 17329984 DOI: 10.1017/S1092852900025906 |
0.523 |
|
| 2007 |
Swartz MS, Perkins DO, Stroup TS, Davis SM, Capuano G, Rosenheck RA, Reimherr F, McGee MF, Keefe RS, McEvoy JP, Hsiao JK, Lieberman JA. Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. The American Journal of Psychiatry. 164: 428-36. PMID 17329467 DOI: 10.1176/Ajp.2007.164.3.428 |
0.703 |
|
| 2007 |
Stroup TS, Lieberman JA, McEvoy JP, Swartz MS, Davis SM, Capuano GA, Rosenheck RA, Keefe RS, Miller AL, Belz I, Hsiao JK. Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study. The American Journal of Psychiatry. 164: 415-27. PMID 17329466 DOI: 10.1176/Ajp.2007.164.3.415 |
0.717 |
|
| 2007 |
Lieberman JA, First MB. Renaming schizophrenia British Medical Journal. 334: 108. PMID 17235058 DOI: 10.1136/bmj.39057.662373.80 |
0.422 |
|
| 2007 |
Sullivan PF, Keefe RS, Lange LA, Lange EM, Stroup TS, Lieberman J, Maness PF. NCAM1 and neurocognition in schizophrenia. Biological Psychiatry. 61: 902-10. PMID 17161382 DOI: 10.1016/J.Biopsych.2006.07.036 |
0.673 |
|
| 2007 |
Hwang R, Shinkai T, De Luca V, Ni X, Potkin SG, Lieberman JA, Meltzer HY, Kennedy JL. Association study of four dopamine D1 receptor gene polymorphisms and clozapine treatment response. Journal of Psychopharmacology (Oxford, England). 21: 718-27. PMID 17092969 DOI: 10.1177/0269881106072341 |
0.4 |
|
| 2007 |
Zai CC, Hwang RW, De Luca V, Müller DJ, King N, Zai GC, Remington G, Meltzer HY, Lieberman JA, Potkin SG, Kennedy JL. Association study of tardive dyskinesia and twelve DRD2 polymorphisms in schizophrenia patients. The International Journal of Neuropsychopharmacology / Official Scientific Journal of the Collegium Internationale Neuropsychopharmacologicum (Cinp). 10: 639-51. PMID 16959057 DOI: 10.1017/S1461145706007152 |
0.343 |
|
| 2007 |
Jarskog LF, Miyamoto S, Lieberman JA. Schizophrenia: new pathological insights and therapies. Annual Review of Medicine. 58: 49-61. PMID 16903799 DOI: 10.1146/Annurev.Med.58.060904.084114 |
0.521 |
|
| 2007 |
Jarskog LF, Gilmore JH, Glantz LA, Gable KL, German TT, Tong RI, Lieberman JA. Caspase-3 activation in rat frontal cortex following treatment with typical and atypical antipsychotics. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 32: 95-102. PMID 16641945 DOI: 10.1038/Sj.Npp.1301074 |
0.405 |
|
| 2007 |
Stroup TS, McEvoy JP, Swartz MS, Hamer RM, Perkins DO, Lieberman JA. Comparison of Antipsychotics for Metabolic Problems (CAMP): A NIMH schizophrenia trials network study Clinical Schizophrenia and Related Psychoses. 1: 69-72. DOI: 10.3371/Csrp.1.1.6 |
0.651 |
|
| 2007 |
Lieberman J, Corcoran C. The impossible dream: can psychiatry prevent psychosis? Early Intervention in Psychiatry. 1: 219-221. DOI: 10.1111/J.1751-7893.2007.00031.X |
0.362 |
|
| 2007 |
Lieberman JA, Buckley PF, Perkins DO. Neuroprotection: A New Strategy in the Treatment of Schizophrenia Cns Spectrums. 12: 1-16. DOI: 10.1017/S1092852900026328 |
0.539 |
|
| 2006 |
Essock SM, Covell NH, Davis SM, Stroup TS, Rosenheck RA, Lieberman JA. Effectiveness of switching antipsychotic medications. The American Journal of Psychiatry. 163: 2090-5. PMID 17151159 DOI: 10.1176/Ajp.2006.163.12.2090 |
0.611 |
|
| 2006 |
Rosenheck RA, Leslie DL, Sindelar J, Miller EA, Lin H, Stroup TS, McEvoy J, Davis SM, Keefe RS, Swartz M, Perkins DO, Hsiao JK, Lieberman J. Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. The American Journal of Psychiatry. 163: 2080-9. PMID 17151158 DOI: 10.1176/Ajp.2006.163.12.2080 |
0.692 |
|
| 2006 |
Hoptman MJ, Volavka J, Czobor P, Gerig G, Chakos M, Blocher J, Citrome LL, Sheitman B, Lindenmayer JP, Lieberman JA, Bilder RM. Aggression and quantitative MRI measures of caudate in patients with chronic schizophrenia or schizoaffective disorder. The Journal of Neuropsychiatry and Clinical Neurosciences. 18: 509-15. PMID 17135376 DOI: 10.1176/Appi.Neuropsych.18.4.509 |
0.454 |
|
| 2006 |
Lieberman JA. Neurobiology and the natural history of schizophrenia The Journal of Clinical Psychiatry. 67. PMID 17107237 |
0.416 |
|
| 2006 |
Duncan GE, Moy SS, Lieberman JA, Koller BH. Typical and atypical antipsychotic drug effects on locomotor hyperactivity and deficits in sensorimotor gating in a genetic model of NMDA receptor hypofunction. Pharmacology, Biochemistry, and Behavior. 85: 481-91. PMID 17097724 DOI: 10.1016/J.Pbb.2006.09.017 |
0.32 |
|
| 2006 |
van der Stelt O, Lieberman JA, Belger A. Attentional modulation of early-stage visual processing in schizophrenia. Brain Research. 1125: 194-8. PMID 17087921 DOI: 10.1016/J.Brainres.2006.09.099 |
0.446 |
|
| 2006 |
Jarskog LF, Lieberman JA. Neuroprotection in schizophrenia Journal of Clinical Psychiatry. 67. PMID 17081076 DOI: 10.4088/Jcp.0906E09 |
0.477 |
|
| 2006 |
Schneider LS, Tariot PN, Dagerman KS, Davis SM, Hsiao JK, Ismail MS, Lebowitz BD, Lyketsos CG, Ryan JM, Stroup TS, Sultzer DL, Weintraub D, Lieberman JA. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. The New England Journal of Medicine. 355: 1525-38. PMID 17035647 DOI: 10.1056/Nejmoa061240 |
0.591 |
|
| 2006 |
Lieberman JA. Comparative effectiveness of antipsychotic drugs: A commentary on Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1) and Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Archives of General Psychiatry. 63: 1069-1072. PMID 17015808 DOI: 10.1001/Archpsyc.63.10.1069 |
0.467 |
|
| 2006 |
Marx CE, Shampine LJ, Duncan GE, VanDoren MJ, Grobin AC, Massing MW, Madison RD, Bradford DW, Butterfield MI, Lieberman JA, Morrow AL. Clozapine markedly elevates pregnenolone in rat hippocampus, cerebral cortex, and serum: candidate mechanism for superior efficacy? Pharmacology, Biochemistry, and Behavior. 84: 598-608. PMID 16962649 DOI: 10.1016/J.Pbb.2006.07.026 |
0.35 |
|
| 2006 |
Zai G, Müller DJ, Volavka J, Czobor P, Lieberman JA, Meltzer HY, Kennedy JL. Family and case-control association study of the tumor necrosis factor-alpha (TNF-alpha) gene with schizophrenia and response to antipsychotic medication. Psychopharmacology. 188: 171-82. PMID 16932925 DOI: 10.1007/S00213-006-0482-4 |
0.348 |
|
| 2006 |
Zhong KX, Sweitzer DE, Hamer RM, Lieberman JA. Comparison of quetiapine and risperidone in the treatment of schizophrenia: A randomized, double-blind, flexible-dose, 8-week study. The Journal of Clinical Psychiatry. 67: 1093-103. PMID 16889453 DOI: 10.4088/Jcp.V67N0712 |
0.515 |
|
| 2006 |
Green AI, Lieberman JA, Hamer RM, Glick ID, Gur RE, Kahn RS, McEvoy JP, Perkins DO, Rothschild AJ, Sharma T, Tohen MF, Woolson S, Zipursky RB. Olanzapine and haloperidol in first episode psychosis: two-year data. Schizophrenia Research. 86: 234-43. PMID 16887334 DOI: 10.1016/J.Schres.2006.06.021 |
0.483 |
|
| 2006 |
Nasrallah HA, Meyer JM, Goff DC, McEvoy JP, Davis SM, Stroup TS, Lieberman JA. Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophrenia Research. 86: 15-22. PMID 16884895 DOI: 10.1016/J.Schres.2006.06.026 |
0.676 |
|
| 2006 |
Perlick DA, Rosenheck RA, Kaczynski R, Swartz MS, Cañive JM, Lieberman JA. Components and correlates of family burden in schizophrenia Psychiatric Services. 57: 1117-1125. PMID 16870962 DOI: 10.1176/Ps.2006.57.8.1117 |
0.425 |
|
| 2006 |
Swartz MS, Wagner HR, Swanson JW, Stroup TS, McEvoy JP, McGee M, Miller DD, Reimherr F, Khan A, Cañive JM, Lieberman JA. Substance use and psychosocial functioning in schizophrenia among new enrollees in the NIMH CATIE study. Psychiatric Services (Washington, D.C.). 57: 1110-6. PMID 16870961 DOI: 10.1176/Ps.2006.57.8.1110 |
0.688 |
|
| 2006 |
Chwastiak LA, Rosenheck RA, McEvoy JP, Keefe RS, Swartz MS, Lieberman JA. Interrelationships of psychiatric symptom severity, medical comorbidity, and functioning in schizophrenia. Psychiatric Services (Washington, D.C.). 57: 1102-9. PMID 16870960 DOI: 10.1176/Ps.2006.57.8.1102 |
0.481 |
|
| 2006 |
Lieberman JA, Jarskog LF, Malaspina D. Preventing clinical deterioration in the course of schizophrenia: The potential for neuroprotection Journal of Clinical Psychiatry. 67: 983-990. PMID 16848659 DOI: 10.4088/Jcp.V67N0616 |
0.491 |
|
| 2006 |
Venkatraman TN, Hamer RM, Perkins DO, Song AW, Lieberman JA, Steen RG. Single-voxel 1H PRESS at 4.0 T: precision and variability of measurements in anterior cingulate and hippocampus. Nmr in Biomedicine. 19: 484-91. PMID 16763968 DOI: 10.1002/Nbm.1055 |
0.319 |
|
| 2006 |
McEvoy JP, Johnson J, Perkins D, Lieberman JA, Hamer RM, Keefe RS, Tohen M, Glick ID, Sharma T. Insight in first-episode psychosis. Psychological Medicine. 36: 1385-93. PMID 16740175 DOI: 10.1017/S0033291706007793 |
0.342 |
|
| 2006 |
Steen RG, Mull C, McClure R, Hamer RM, Lieberman JA. Brain volume in first-episode schizophrenia: systematic review and meta-analysis of magnetic resonance imaging studies. The British Journal of Psychiatry : the Journal of Mental Science. 188: 510-8. PMID 16738340 DOI: 10.1192/Bjp.188.6.510 |
0.463 |
|
| 2006 |
Swanson JW, Swartz MS, Van Dorn RA, Elbogen EB, Wagner HR, Rosenheck RA, Stroup TS, McEvoy JP, Lieberman JA. A national study of violent behavior in persons with schizophrenia. Archives of General Psychiatry. 63: 490-9. PMID 16651506 DOI: 10.1001/Archpsyc.63.5.490 |
0.668 |
|
| 2006 |
Keefe RS, Bilder RM, Harvey PD, Davis SM, Palmer BW, Gold JM, Meltzer HY, Green MF, Miller DD, Canive JM, Adler LW, Manschreck TC, Swartz M, Rosenheck R, Perkins DO, ... Lieberman JA, et al. Baseline neurocognitive deficits in the CATIE schizophrenia trial. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 31: 2033-46. PMID 16641947 DOI: 10.1038/Sj.Npp.1301072 |
0.68 |
|
| 2006 |
Lieberman JA, Malaspina D, Jarskog LF. Preventing clinical deterioration in the course of schizophrenia: the potential for neuroprotection. Cns Spectrums. 11: suppl 1-13; quiz sup. PMID 16641837 |
0.418 |
|
| 2006 |
Stroup TS, Lieberman JA, McEvoy JP, Swartz MS, Davis SM, Rosenheck RA, Perkins DO, Keefe RS, Davis CE, Severe J, Hsiao JK. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. The American Journal of Psychiatry. 163: 611-22. PMID 16585435 DOI: 10.1176/Appi.Ajp.163.4.611 |
0.725 |
|
| 2006 |
McEvoy JP, Lieberman JA, Stroup TS, Davis SM, Meltzer HY, Rosenheck RA, Swartz MS, Perkins DO, Keefe RS, Davis CE, Severe J, Hsiao JK. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. The American Journal of Psychiatry. 163: 600-10. PMID 16585434 DOI: 10.1176/Appi.Ajp.163.4.600 |
0.716 |
|
| 2006 |
Swartz MS, Wagner HR, Swanson JW, Stroup TS, McEvoy JP, Canive JM, Miller DD, Reimherr F, McGee M, Khan A, Van Dorn R, Rosenheck RA, Lieberman JA. Substance use in persons with schizophrenia: baseline prevalence and correlates from the NIMH CATIE study. The Journal of Nervous and Mental Disease. 194: 164-72. PMID 16534433 DOI: 10.1097/01.Nmd.0000202575.79453.6E |
0.635 |
|
| 2006 |
Perkins DO, Johnson JL, Hamer RM, Zipursky RB, Keefe RS, Centorrhino F, Green AI, Glick IB, Kahn RS, Sharma T, Tohen M, McEvoy JP, Weiden PJ, Lieberman JA. Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode. Schizophrenia Research. 83: 53-63. PMID 16529910 DOI: 10.1016/J.Schres.2005.10.016 |
0.432 |
|
| 2006 |
Stroup TS, Alves WM, Hamer RM, Lieberman JA. Clinical trials for antipsychotic drugs: design conventions, dilemmas and innovations. Nature Reviews. Drug Discovery. 5: 133-46. PMID 16518380 DOI: 10.1038/Nrd1956 |
0.624 |
|
| 2006 |
Rosenheck R, Leslie D, Keefe R, McEvoy J, Swartz M, Perkins D, Stroup S, Hsiao JK, Lieberman J. Barriers to employment for people with schizophrenia. The American Journal of Psychiatry. 163: 411-7. PMID 16513861 DOI: 10.1176/Appi.Ajp.163.3.411 |
0.513 |
|
| 2006 |
Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, Möller HJ, Altamura AC, Andreasen N, Barnes TRE, Beckmann H, Ciprian-Ollivier J, Crow T, David A, Davidson M, Deakin B, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: Long-term treatment of schizophrenia World Journal of Biological Psychiatry. 7: 5-40. PMID 16509050 DOI: 10.1080/15622970500483177 |
0.398 |
|
| 2006 |
Umbricht DS, Bates JA, Lieberman JA, Kane JM, Javitt DC. Electrophysiological indices of automatic and controlled auditory information processing in first-episode, recent-onset and chronic schizophrenia. Biological Psychiatry. 59: 762-72. PMID 16497277 DOI: 10.1016/J.Biopsych.2005.08.030 |
0.422 |
|
| 2006 |
Bilder RM, Reiter G, Bates J, Lencz T, Szeszko P, Goldman RS, Robinson D, Lieberman JA, Kane JM. Cognitive development in schizophrenia: follow-back from the first episode. Journal of Clinical and Experimental Neuropsychology. 28: 270-82. PMID 16484098 DOI: 10.1080/13803390500360554 |
0.459 |
|
| 2006 |
Merrill DB, Ahmari SE, Bradford JM, Lieberman JA. Myocarditis during clozapine treatment. The American Journal of Psychiatry. 163: 204-8. PMID 16449471 DOI: 10.1176/Appi.Ajp.163.2.204 |
0.464 |
|
| 2006 |
Lieberman JA, Hsiao JK. Interpreting the results of the CATIE study [1] Psychiatric Services. 57: 139. PMID 16399980 DOI: 10.1176/Appi.Ps.57.1.139 |
0.508 |
|
| 2006 |
Marx CE, Stevens RD, Shampine LJ, Uzunova V, Trost WT, Butterfield MI, Massing MW, Hamer RM, Morrow AL, Lieberman JA. Neuroactive steroids are altered in schizophrenia and bipolar disorder: relevance to pathophysiology and therapeutics. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 31: 1249-63. PMID 16319920 DOI: 10.1038/Sj.Npp.1300952 |
0.449 |
|
| 2006 |
Rosenheck R, Stroup S, Keefe RS, McEvoy J, Swartz M, Perkins D, Hsiao J, Shumway M, Lieberman J. Measuring outcome priorities and preferences in people with schizophrenia. The British Journal of Psychiatry : the Journal of Mental Science. 187: 529-36. PMID 16319405 DOI: 10.1192/Bjp.187.6.529 |
0.403 |
|
| 2006 |
Glantz LA, Gilmore JH, Lieberman JA, Jarskog LF. Apoptotic mechanisms and the synaptic pathology of schizophrenia. Schizophrenia Research. 81: 47-63. PMID 16226876 DOI: 10.1016/J.Schres.2005.08.014 |
0.391 |
|
| 2006 |
Keefe RS, Seidman LJ, Christensen BK, Hamer RM, Sharma T, Sitskoorn MM, Rock SL, Woolson S, Tohen M, Tollefson GD, Sanger TM, Lieberman JA. Long-term neurocognitive effects of olanzapine or low-dose haloperidol in first-episode psychosis. Biological Psychiatry. 59: 97-105. PMID 16140282 DOI: 10.1016/J.Biopsych.2005.06.022 |
0.351 |
|
| 2006 |
Lieberman JA. Neurobiology and the Natural History of Schizophrenia The Journal of Clinical Psychiatry. 67: e11. DOI: 10.4088/Jcp.1006E14 |
0.512 |
|
| 2006 |
Perlick DA, Rosenheck RA, Kaczynski R, Swartz MS, Cañive JM, Lieberman JA. Components and correlates of family burden in schizophrenia. Psychiatric Services. 57: 1117-1125. DOI: 10.1176/Appi.Ps.57.8.1117 |
0.425 |
|
| 2006 |
Chwastiak LA, Rosenheck RA, McEvoy JP, Keefe RS, Swartz MS, Lieberman JA. Interrelationships of psychiatric symptom severity, medical comorbidity, and functioning in schizophrenia. Psychiatric Services. 57: 1102-1109. DOI: 10.1176/Appi.Ps.57.8.1102 |
0.453 |
|
| 2006 |
Lieberman JA, Stroup TS, McEVOY JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RSE, Davis SM, Davis CE, Hsiao J, Severe J, Lebowitz BD. Dr. Lieberman and Colleagues Reply American Journal of Psychiatry. 163: 555-556. DOI: 10.1176/Appi.Ajp.163.3.555-A |
0.514 |
|
| 2006 |
Sheitman BB, Lee H, Strous R, Lieberman JA. Erratum: The evaluation and treatment of first-episode psychosis (Schizophrenia Bulletin (1997) 23 (653-661)) Schizophrenia Bulletin. 32. DOI: 10.1093/Schbul/Sbj039 |
0.519 |
|
| 2006 |
Rappard F, Loebel A, Warrington L, Siu C, Lieberman J. P.3.a.047 Remission in schizophrenia: a comparison of 2 dose regimens of ziprasidone versus haloperidol in a 40-week core and 3-year double-blind continuation study European Neuropsychopharmacology. 16: S390. DOI: 10.1016/S0924-977X(06)70476-X |
0.348 |
|
| 2006 |
Perkins D, Gu H, Zipursky R, Gerig G, Lieberman J. TC18C MRI OF BRAIN VOLUMES AT THE PRODROME AND FIRST EPISODE STAGES OF SCHIZOPHRENIA Schizophrenia Research. 86: S59. DOI: 10.1016/S0920-9964(06)70176-1 |
0.32 |
|
| 2005 |
Kraus JE, Sheitman BB, Cook A, Reviere R, Lieberman JA. Olanzapine versus risperidone in newly admitted acutely ill psychotic patients Journal of Clinical Psychiatry. 66: 1564-1568. PMID 16401158 DOI: 10.4088/Jcp.V66N1211 |
0.317 |
|
| 2005 |
Nemeroff CB, Lieberman JA, Weiden PJ, Harvey PD, Newcomer JW, Schatzberg AF, Kilts CD, Daniel DG. From clinical research to clinical practice: a 4-year review of ziprasidone. Cns Spectrums. 10: 1-20. PMID 16381088 DOI: 10.1017/S1092852900019842 |
0.482 |
|
| 2005 |
Penn DL, Waldheter EJ, Perkins DO, Mueser KT, Lieberman JA. Psychosocial treatment for first-episode psychosis: a research update. The American Journal of Psychiatry. 162: 2220-32. PMID 16330584 DOI: 10.1176/Appi.Ajp.162.12.2220 |
0.314 |
|
| 2005 |
Hoptman MJ, Volavka J, Weiss EM, Czobor P, Szeszko PR, Gerig G, Chakos M, Blocher J, Citrome LL, Lindenmayer JP, Sheitman B, Lieberman JA, Bilder RM. Quantitative MRI measures of orbitofrontal cortex in patients with chronic schizophrenia or schizoaffective disorder. Psychiatry Research. 140: 133-45. PMID 16253482 DOI: 10.1016/J.Pscychresns.2005.07.004 |
0.451 |
|
| 2005 |
Gunduz-Bruce H, McMeniman M, Robinson DG, Woerner MG, Kane JM, Schooler NR, Lieberman JA. Duration of untreated psychosis and time to treatment response for delusions and hallucinations. The American Journal of Psychiatry. 162: 1966-9. PMID 16199847 DOI: 10.1176/Appi.Ajp.162.10.1966 |
0.463 |
|
| 2005 |
Perkins DO, Gu H, Boteva K, Lieberman JA. Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis. The American Journal of Psychiatry. 162: 1785-804. PMID 16199825 DOI: 10.1176/Appi.Ajp.162.10.1785 |
0.43 |
|
| 2005 |
Goff DC, Sullivan LM, McEvoy JP, Meyer JM, Nasrallah HA, Daumit GL, Lamberti S, D'Agostino RB, Stroup TS, Davis S, Lieberman JA. A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophrenia Research. 80: 45-53. PMID 16198088 DOI: 10.1016/J.Schres.2005.08.010 |
0.646 |
|
| 2005 |
Stroup S, Appelbaum P, Swartz M, Patel M, Davis S, Jeste D, Kim S, Keefe R, Manschreck T, McEvoy J, Lieberman J. Decision-making capacity for research participation among individuals in the CATIE schizophrenia trial. Schizophrenia Research. 80: 1-8. PMID 16182516 DOI: 10.1016/J.Schres.2005.08.007 |
0.434 |
|
| 2005 |
Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, Möller HJ, Altamura AC, Andreasen N, Barnes TRE, Beckmann H, Ciprian-Ollivier J, Crow T, David A, Davidson M, Deakin B, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: Acute treatment of schizophrenia World Journal of Biological Psychiatry. 6: 132-191. PMID 16173147 DOI: 10.1080/15622970510030090 |
0.511 |
|
| 2005 |
Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. The New England Journal of Medicine. 353: 1209-23. PMID 16172203 DOI: 10.1056/Nejmoa051688 |
0.656 |
|
| 2005 |
Miller DD, McEvoy JP, Davis SM, Caroff SN, Saltz BL, Chakos MH, Swartz MS, Keefe RS, Rosenheck RA, Stroup TS, Lieberman JA. Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial. Schizophrenia Research. 80: 33-43. PMID 16171976 DOI: 10.1016/J.Schres.2005.07.034 |
0.703 |
|
| 2005 |
Müller DJ, De Luca V, Sicard T, King N, Hwang R, Volavka J, Czobor P, Sheitman BB, Lindenmayer JP, Citrome L, McEvoy JP, Lieberman JA, Meltzer HY, Kennedy JL. Suggestive association between the C825T polymorphism of the G-protein beta3 subunit gene (GNB3) and clinical improvement with antipsychotics in schizophrenia. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 15: 525-31. PMID 16139171 DOI: 10.1016/J.Euroneuro.2005.02.001 |
0.383 |
|
| 2005 |
McEvoy JP, Meyer JM, Goff DC, Nasrallah HA, Davis SM, Sullivan L, Meltzer HY, Hsiao J, Scott Stroup T, Lieberman JA. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophrenia Research. 80: 19-32. PMID 16137860 DOI: 10.1016/J.Schres.2005.07.014 |
0.485 |
|
| 2005 |
Pinkham A, Penn D, Wangelin B, Perkins D, Gerig G, Gu H, Lieberman J. Facial emotion perception and fusiform gyrus volume in first episode schizophrenia. Schizophrenia Research. 79: 341-3. PMID 16125902 DOI: 10.1016/J.Schres.2005.07.012 |
0.411 |
|
| 2005 |
Meyer JM, Nasrallah HA, McEvoy JP, Goff DC, Davis SM, Chakos M, Patel JK, Keefe RS, Stroup TS, Lieberman JA. The Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE) Schizophrenia Trial: clinical comparison of subgroups with and without the metabolic syndrome. Schizophrenia Research. 80: 9-18. PMID 16125372 DOI: 10.1016/J.Schres.2005.07.015 |
0.654 |
|
| 2005 |
Steen RG, Hamer RM, Lieberman JA. Measurement of brain metabolites by 1H magnetic resonance spectroscopy in patients with schizophrenia: A systematic review and meta-analysis Neuropsychopharmacology. 30: 1949-1962. PMID 16123764 DOI: 10.1038/Sj.Npp.1300850 |
0.383 |
|
| 2005 |
Shinkai T, De Luca V, Hwang R, Matsumoto C, Hori H, Ohmori O, Remington G, Meltzer HY, Lieberman JA, Potkin SG, Nakamura J, Kennedy JL. Association study between a functional glutathione S-transferase (GSTP1) gene polymorphism (Ile105Val) and tardive dyskinesia. Neuroscience Letters. 388: 116-20. PMID 16039055 DOI: 10.1016/J.Neulet.2005.06.038 |
0.342 |
|
| 2005 |
Strakowski SM, Johnson JL, Delbello MP, Hamer RM, Green AI, Tohen M, Lieberman JA, Glick I, Patel JK. Quality of life during treatment with haloperidol or olanzapine in the year following a first psychotic episode. Schizophrenia Research. 78: 161-9. PMID 15950436 DOI: 10.1016/J.Schres.2005.04.017 |
0.45 |
|
| 2005 |
van der Stelt O, Lieberman JA, Belger A. Auditory P300 in high-risk, recent-onset and chronic schizophrenia. Schizophrenia Research. 77: 309-20. PMID 15944141 DOI: 10.1016/J.Schres.2005.04.024 |
0.5 |
|
| 2005 |
Volavka J, Nolan KA, Kline L, Czobor P, Citrome L, Sheitman B, Lindenmayer JP, McEvoy J, Lieberman JA. Efficacy of clozapine, olanzapine, risperidone, and haloperidol in schizophrenia and schizoaffective disorder assessed with nurses observation scale for inpatient evaluation. Schizophrenia Research. 76: 127-9. PMID 15927808 DOI: 10.1016/J.Schres.2004.11.007 |
0.424 |
|
| 2005 |
Jarskog LF, Glantz LA, Gilmore JH, Lieberman JA. Apoptotic mechanisms in the pathophysiology of schizophrenia Progress in Neuro-Psychopharmacology and Biological Psychiatry. 29: 846-858. PMID 15908096 DOI: 10.1016/J.Pnpbp.2005.03.010 |
0.467 |
|
| 2005 |
Hwang R, Shinkai T, De Luca V, Müller DJ, Ni X, Macciardi F, Potkin S, Lieberman JA, Meltzer HY, Kennedy JL. Association study of 12 polymorphisms spanning the dopamine D(2) receptor gene and clozapine treatment response in two treatment refractory/intolerant populations. Psychopharmacology. 181: 179-87. PMID 15830237 DOI: 10.1007/S00213-005-2223-5 |
0.343 |
|
| 2005 |
Müller DJ, Klempan TA, De Luca V, Sicard T, Volavka J, Czobor P, Sheitman BB, Lindenmayer JP, Citrome L, McEvoy JP, Lieberman JA, Honer WG, Kennedy JL. The SNAP-25 gene may be associated with clinical response and weight gain in antipsychotic treatment of schizophrenia. Neuroscience Letters. 379: 81-9. PMID 15823421 DOI: 10.1016/J.Neulet.2004.12.037 |
0.42 |
|
| 2005 |
Lieberman JA, Tollefson GD, Charles C, Zipursky R, Sharma T, Kahn RS, Keefe RS, Green AI, Gur RE, McEvoy J, Perkins D, Hamer RM, Gu H, Tohen M. Antipsychotic drug effects on brain morphology in first-episode psychosis. Archives of General Psychiatry. 62: 361-70. PMID 15809403 DOI: 10.1001/Archpsyc.62.4.361 |
0.455 |
|
| 2005 |
Styner M, Lieberman JA, McClure RK, Weinberger DR, Jones DW, Gerig G. Morphometric analysis of lateral ventricles in schizophrenia and healthy controls regarding genetic and disease-specific factors. Proceedings of the National Academy of Sciences of the United States of America. 102: 4872-7. PMID 15772166 DOI: 10.1073/Pnas.0501117102 |
0.434 |
|
| 2005 |
Morey RA, Inan S, Mitchell TV, Perkins DO, Lieberman JA, Belger A. Imaging frontostriatal function in ultra-high-risk, early, and chronic schizophrenia during executive processing. Archives of General Psychiatry. 62: 254-62. PMID 15753238 DOI: 10.1001/Archpsyc.62.3.254 |
0.35 |
|
| 2005 |
De Luca V, Vincent JB, Müller DJ, Hwang R, Shinkai T, Volavka J, Czobor P, Sheitman BB, Lindenmayer JP, Citrome L, McEvoy JP, Lieberman JA, Kennedy JL. Identification of a naturally occurring 21 bp deletion in alpha 2c noradrenergic receptor gene and cognitive correlates to antipsychotic treatment. Pharmacological Research. 51: 381-4. PMID 15683753 DOI: 10.1016/J.Phrs.2004.10.013 |
0.477 |
|
| 2005 |
Chakos MH, Schobel SA, Gu H, Gerig G, Bradford D, Charles C, Lieberman JA. Duration of illness and treatment effects on hippocampal volume in male patients with schizophrenia. The British Journal of Psychiatry : the Journal of Mental Science. 186: 26-31. PMID 15630120 DOI: 10.1192/Bjp.186.1.26 |
0.473 |
|
| 2005 |
Nolan KA, Volavka J, Czobor P, Sheitman B, Lindenmayer JP, Citrome LL, McEvoy J, Lieberman JA. Aggression and psychopathology in treatment-resistant inpatients with schizophrenia and schizoaffective disorder. Journal of Psychiatric Research. 39: 109-15. PMID 15504429 DOI: 10.1016/J.Jpsychires.2004.04.010 |
0.427 |
|
| 2005 |
Miyamoto S, Duncan GE, Marx CE, Lieberman JA. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Molecular Psychiatry. 10: 79-104. PMID 15289815 DOI: 10.1038/Sj.Mp.4001556 |
0.484 |
|
| 2005 |
Lieberman JA. Recent Advances in the Clinical Use of Atypical Antipsychotics Cns Spectrums. 10: 4-4. DOI: 10.1017/S1092852900025153 |
0.347 |
|
| 2005 |
Marx CE, Grobin AC, Deutch AY, Lieberman JA. Chapter 3.5 Atypical antipsychotic drugs and stress Techniques in the Behavioral and Neural Sciences. 15: 301-313. DOI: 10.1016/S0921-0709(05)80061-6 |
0.403 |
|
| 2004 |
Stroup TS, McEvoy JP, Lieberman JA. Revised PORT recommendations Schizophrenia Bulletin. 30: 609-611. PMID 15631251 DOI: 10.1093/Oxfordjournals.Schbul.A007106 |
0.663 |
|
| 2004 |
van der Stelt O, Belger A, Lieberman JA. Macroscopic fast neuronal oscillations and synchrony in schizophrenia. Proceedings of the National Academy of Sciences of the United States of America. 101: 17567-8. PMID 15601768 DOI: 10.1073/Pnas.0407688101 |
0.468 |
|
| 2004 |
Miyamoto S, Snouwaert JN, Koller BH, Moy SS, Lieberman JA, Duncan GE. Amphetamine-induced Fos is reduced in limbic cortical regions but not in the caudate or accumbens in a genetic model of NMDA receptor hypofunction. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 29: 2180-8. PMID 15467708 DOI: 10.1038/Sj.Npp.1300548 |
0.315 |
|
| 2004 |
Styner M, Lieberman JA, Pantazis D, Gerig G. Boundary and medial shape analysis of the hippocampus in schizophrenia. Medical Image Analysis. 8: 197-203. PMID 15450215 DOI: 10.1016/J.Media.2004.06.004 |
0.334 |
|
| 2004 |
Marder SR, Essock SM, Miller AL, Buchanan RW, Casey DE, Davis JM, Kane JM, Lieberman JA, Schooler NR, Covell N, Stroup S, Weissman EM, Wirshing DA, Hall CS, Pogach L, et al. Physical health monitoring of patients with schizophrenia. The American Journal of Psychiatry. 161: 1334-49. PMID 15285957 DOI: 10.1176/Appi.Ajp.161.8.1334 |
0.467 |
|
| 2004 |
Strous RD, Alvir JM, Robinson D, Gal G, Sheitman B, Chakos M, Lieberman JA. Premorbid functioning in schizophrenia: relation to baseline symptoms, treatment response, and medication side effects. Schizophrenia Bulletin. 30: 265-78. PMID 15279045 DOI: 10.1093/Oxfordjournals.Schbul.A007077 |
0.488 |
|
| 2004 |
Duncan GE, Moy SS, Perez A, Eddy DM, Zinzow WM, Lieberman JA, Snouwaert JN, Koller BH. Deficits in sensorimotor gating and tests of social behavior in a genetic model of reduced NMDA receptor function. Behavioural Brain Research. 153: 507-19. PMID 15265649 DOI: 10.1016/J.Bbr.2004.01.008 |
0.329 |
|
| 2004 |
Perkins DO, Lieberman JA, Gu H, Tohen M, McEvoy J, Green AI, Zipursky RB, Strakowski SM, Sharma T, Kahn RS, Gur R, Tollefson G. Predictors of antipsychotic treatment response in patients with first-episode schizophrenia, schizoaffective and schizophreniform disorders British Journal of Psychiatry. 185: 18-24. PMID 15231551 DOI: 10.1192/Bjp.185.1.18 |
0.509 |
|
| 2004 |
Volavka J, Czobor P, Nolan K, Sheitman B, Lindenmayer JP, Citrome L, McEvoy JP, Cooper TB, Lieberman JA. Overt aggression and psychotic symptoms in patients with schizophrenia treated with clozapine, olanzapine, risperidone, or haloperidol. Journal of Clinical Psychopharmacology. 24: 225-8. PMID 15206671 DOI: 10.1097/01.Jcp.0000117424.05703.29 |
0.49 |
|
| 2004 |
Keefe RS, Seidman LJ, Christensen BK, Hamer RM, Sharma T, Sitskoorn MM, Lewine RR, Yurgelun-Todd DA, Gur RC, Tohen M, Tollefson GD, Sanger TM, Lieberman JA. Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol. The American Journal of Psychiatry. 161: 985-95. PMID 15169686 DOI: 10.1176/Appi.Ajp.161.6.985 |
0.435 |
|
| 2004 |
Lindenmayer JP, Czobor P, Volavka J, Lieberman JA, Citrome L, Sheitman B, McEvoy JP, Cooper TB, Chakos M. Effects of atypical antipsychotics on the syndromal profile in treatment-resistant schizophrenia. The Journal of Clinical Psychiatry. 65: 551-6. PMID 15119920 DOI: 10.4088/Jcp.V65N0416 |
0.519 |
|
| 2004 |
Volavka J, Kennedy JL, Ni X, Czobor P, Nolan K, Sheitman B, Lindenmayer JP, Citrome L, McEvoy J, Lieberman JA. COMT158 Polymorphism and Hostility American Journal of Medical Genetics - Neuropsychiatric Genetics. 127: 28-29. PMID 15108175 DOI: 10.1002/Ajmg.B.20149 |
0.425 |
|
| 2004 |
Alamy SS, Jarskog LF, Sheitman BB, Lieberman JA. Secretin in a patient with treatment-resistant schizophrenia and prominent autistic features Schizophrenia Research. 66: 183-186. PMID 15061252 DOI: 10.1016/J.Schres.2003.07.003 |
0.5 |
|
| 2004 |
Sheitman BB, Knable MB, Jarskog LF, Chakos M, Boyce LH, Early J, Lieberman JA. Secretin for refractory schizophrenia. Schizophrenia Research. 66: 177-81. PMID 15061251 DOI: 10.1016/S0920-9964(03)00068-9 |
0.526 |
|
| 2004 |
Green AI, Tohen MF, Hamer RM, Strakowski SM, Lieberman JA, Glick I, Clark WS. First episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidol. Schizophrenia Research. 66: 125-35. PMID 15061244 DOI: 10.1016/J.Schres.2003.08.001 |
0.438 |
|
| 2004 |
Lieberman JA. Dopamine partial agonists: A new class of antipsychotic Cns Drugs. 18: 251-267. PMID 15015905 DOI: 10.2165/00023210-200418040-00005 |
0.396 |
|
| 2004 |
Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO, Kreyenbuhl J, McIntyre JS, Charles SC, Altshuler K, Cook I, Cross CD, Mellman L, Moench LA, Norquist G, et al. Practice Guideline for the Treatment of Partients with Schizophrenia, Second Edition American Journal of Psychiatry. 161: i-iv+1-56. PMID 15000267 |
0.385 |
|
| 2004 |
van der Stelt O, Frye J, Lieberman JA, Belger A. Impaired P3 generation reflects high-level and progressive neurocognitive dysfunction in schizophrenia. Archives of General Psychiatry. 61: 237-48. PMID 14993111 DOI: 10.1001/Archpsyc.61.3.237 |
0.458 |
|
| 2004 |
Volavka J, Czobor P, Cooper TB, Sheitman B, Lindenmayer JP, Citrome L, McEvoy JP, Lieberman JA. Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol. The Journal of Clinical Psychiatry. 65: 57-61. PMID 14744169 DOI: 10.4088/Jcp.V65N0109 |
0.43 |
|
| 2004 |
Jarskog LF, Selinger ES, Lieberman JA, Gilmore JH. Apoptotic Proteins in the Temporal Cortex in Schizophrenia: High Bax/Bcl-2 Ratio without Caspase-3 Activation American Journal of Psychiatry. 161: 109-115. PMID 14702258 DOI: 10.1176/Appi.Ajp.161.1.109 |
0.386 |
|
| 2004 |
Sikich L, Hamer RM, Bashford RA, Sheitman BB, Lieberman JA. A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 29: 133-45. PMID 14583740 DOI: 10.1038/Sj.Npp.1300327 |
0.404 |
|
| 2004 |
Volavka J, Czobor P, Sheitman B, Lindenmayer J, Citrome L, McEvoy JP, Cooper TB, Chakos M, Lieberman JA. Clozapine, Olanzapine, Risperidone, and Haloperidol in the Treatment of Patients With Chronic Schizophrenia and Schizoaffective Disorder Focus. 2: 59-67. DOI: 10.1176/FOC.2.1.59 |
0.415 |
|
| 2003 |
Miyamoto S, LaMantia AS, Duncan GE, Sullivan P, Gilmore JH, Lieberman JA. Recent advances in the neurobiology of schizophrenia. Molecular Interventions. 3: 27-39. PMID 14993436 DOI: 10.1124/Mi.3.1.27 |
0.42 |
|
| 2003 |
Maynard TM, Haskell GT, Peters AZ, Sikich L, Lieberman JA, LaMantia AS. A comprehensive analysis of 22q11 gene expression in the developing and adult brain. Proceedings of the National Academy of Sciences of the United States of America. 100: 14433-8. PMID 14614146 DOI: 10.1073/Pnas.2235651100 |
0.332 |
|
| 2003 |
Bradford DW, Perkins DO, Lieberman JA. Pharmacological Management of First-Episode Schizophrenia and Related Nonaffective Psychoses Drugs. 63: 2265-2283. PMID 14524730 DOI: 10.2165/00003495-200363210-00001 |
0.55 |
|
| 2003 |
Szeszko PR, Gunning-Dixon F, Goldman RS, Bates J, Ashtari M, Snyder PJ, Lieberman JA, Bilder RM. Lack of normal association between cerebellar volume and neuropsychological functions in first-episode schizophrenia. The American Journal of Psychiatry. 160: 1884-7. PMID 14514506 DOI: 10.1176/Appi.Ajp.160.10.1884 |
0.473 |
|
| 2003 |
Lieberman JA, Stroup TS. Schizophrenia, VI: Treatments The American Journal of Psychiatry. 160: 1748. PMID 14514482 DOI: 10.1176/Appi.Ajp.160.10.1748 |
0.674 |
|
| 2003 |
Stroup TS, McEvoy JP, Swartz MS, Byerly MJ, Glick ID, Canive JM, McGee MF, Simpson GM, Stevens MC, Lieberman JA. The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophrenia Bulletin. 29: 15-31. PMID 12908658 DOI: 10.1093/Oxfordjournals.Schbul.A006986 |
0.656 |
|
| 2003 |
Lieberman JA, Stroup TS. Guest editors' introduction: What can large pragmatic clinical trials do for public mental health care? Schizophrenia Bulletin. 29: 1-6. PMID 12908656 DOI: 10.1093/Oxfordjournals.Schbul.A006979 |
0.585 |
|
| 2003 |
Woerner MG, Robinson DG, Alvir JM, Sheitman BB, Lieberman JA, Kane JM. Clozapine as a first treatment for schizophrenia. The American Journal of Psychiatry. 160: 1514-6. PMID 12900316 DOI: 10.1176/Appi.Ajp.160.8.1514 |
0.531 |
|
| 2003 |
Lieberman JA, Tollefson G, Tohen M, Green AI, Gur RE, Kahn R, McEvoy J, Perkins D, Sharma T, Zipursky R, Wei H, Hamer RM. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. The American Journal of Psychiatry. 160: 1396-404. PMID 12900300 DOI: 10.1176/Appi.Ajp.160.8.1396 |
0.481 |
|
| 2003 |
Pinkham AE, Penn DL, Perkins DO, Lieberman J. Implications for the neural basis of social cognition for the study of schizophrenia. The American Journal of Psychiatry. 160: 815-24. PMID 12727681 DOI: 10.1176/Appi.Ajp.160.5.815 |
0.407 |
|
| 2003 |
Lieberman JA, Phillips M, Gu H, Stroup S, Zhang P, Kong L, Ji Z, Koch G, Hamer RM. Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 28: 995-1003. PMID 12700715 DOI: 10.1038/Sj.Npp.1300157 |
0.503 |
|
| 2003 |
Boteva K, Lieberman J. Reconsidering the classification of schizophrenia and manic depressive illness--a critical analysis and new conceptual model. The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry. 4: 81-92. PMID 12692779 DOI: 10.3109/15622970309167956 |
0.443 |
|
| 2003 |
Duncan GE, Miyamoto S, Lieberman JA. Chronic administration of haloperidol and olanzapine attenuates ketamine-induced brain metabolic activation. The Journal of Pharmacology and Experimental Therapeutics. 305: 999-1005. PMID 12626664 DOI: 10.1124/Jpet.102.048140 |
0.318 |
|
| 2003 |
Lencz T, Bilder RM, Turkel E, Goldman RS, Robinson D, Kane JM, Lieberman JA. Impairments in perceptual competency and maintenance on a visual delayed match-to-sample test in first-episode schizophrenia. Archives of General Psychiatry. 60: 238-43. PMID 12622656 DOI: 10.1001/Archpsyc.60.3.238 |
0.403 |
|
| 2003 |
Szeszko PR, Gunning-Dixon F, Ashtari M, Snyder PJ, Lieberman JA, Bilder RM. Reversed cerebellar asymmetry in men with first-episode schizophrenia. Biological Psychiatry. 53: 450-9. PMID 12614998 DOI: 10.1016/S0006-3223(02)01529-9 |
0.504 |
|
| 2003 |
Lindenmayer JP, Czobor P, Volavka J, Citrome L, Sheitman B, McEvoy JP, Cooper TB, Chakos M, Lieberman JA. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. The American Journal of Psychiatry. 160: 290-6. PMID 12562575 DOI: 10.1176/Appi.Ajp.160.2.290 |
0.487 |
|
| 2003 |
Marx CE, VanDoren MJ, Duncan GE, Lieberman JA, Morrow AL. Olanzapine and clozapine increase the GABAergic neuroactive steroid allopregnanolone in rodents. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 28: 1-13. PMID 12496935 DOI: 10.1038/Sj.Npp.1300015 |
0.322 |
|
| 2003 |
Kennedy J, Klempan T, Mueller D, Wong A, Volavka J, Czobor P, Lieberman J. Molecular genetics of neurodevelopment and treatment response in psychosis Annals of General Hospital Psychiatry. 2: 1-1. DOI: 10.1186/1475-2832-2-S1-S131 |
0.336 |
|
| 2003 |
McClure RK, Lieberman JA. Neurodevelopmental and neurodegenerative hypotheses of schizophrenia: A review and critique Current Opinion in Psychiatry. 16: S15-S28. DOI: 10.1097/00001504-200304002-00004 |
0.497 |
|
| 2003 |
Kahn R, Lieberman J, Charles C, Sharma T, Zipursky R, Gur R, Tohen M, Green A, McEvoy J, Perkins D, Hamer R, Nemeroff C, Rothschild A, Kuldau J, Strakowski S, et al. P.2.131 Antipsychotic treatment effects on progression of brain pathomorphology in first episode schizophrenia European Neuropsychopharmacology. 13: S337. DOI: 10.1016/S0924-977X(03)92084-0 |
0.395 |
|
| 2003 |
Sharma T, Lieberman J, McEvoy J, Perkins D, Hamer R, Zipursky R, Kahn R, Gur R, Centorrino F, Glick I, Green A, Nemeroff C, Rothschild A, Strakowski S, Tohen M, et al. S.14.05 Long-term efficacy and safety of atypical and conventional antipsychotic drugs in first episode schizophrenia European Neuropsychopharmacology. 13: S134-S135. DOI: 10.1016/S0924-977X(03)91655-5 |
0.333 |
|
| 2003 |
Styner M, Gerig G, Kistner E, Muller K, Lieberman J. Age and treatment related local hippocampal changes in schizophrenia explained by a novel shape analysis method Schizophrenia Research. 60: 208. DOI: 10.1016/S0920-9964(03)81151-9 |
0.325 |
|
| 2003 |
Gerig G, Styner M, Jones D, Weinberger D, Lieberman J. Ventricular shape of monozygotic twins discordant for schizophrenia reflects vulnerability Schizophrenia Research. 60: 194-195. DOI: 10.1016/S0920-9964(03)81111-8 |
0.393 |
|
| 2003 |
Mueller D, Hwang R, Volavka J, Lieberman J, Kennedy J. No association between the COMT VAL158MET polymorphism and antipsychotic response in schizophrenia Schizophrenia Research. 60: 86. DOI: 10.1016/S0920-9964(03)80643-6 |
0.412 |
|
| 2003 |
Glantz L, Gilmore J, Lieberman J, Jarskog L. Decreased PAR-4 in the temporal cortex of subjects with schizophrenia Schizophrenia Research. 60: 62. DOI: 10.1016/S0920-9964(03)80569-8 |
0.34 |
|
| 2003 |
Lieberman J, Charles HC, Sharma T, Zipursky R, Kahn R, Gur R, Tohen M, Green AI, McEvoy J, Perkins D, Hamer RM, Nemeroff C, Rothschild A, Kuldau J, Strakowski S, et al. Antipsychotic treatment effects on progression of brain pathomorphology in first episode schizophrenia Schizophrenia Research. 60: 293. DOI: 10.1016/S0920-9964(03)80491-7 |
0.407 |
|
| 2003 |
Centorrino F, Hamer R, Tohen M, Lieberman J. Drug attitudes and treatment adherence in a clinical trial comparing haloperidol and olanzapine in first episode schizophrenia Schizophrenia Research. 60: 277. DOI: 10.1016/S0920-9964(03)80442-5 |
0.407 |
|
| 2003 |
Umbricht D, Javitt D, Bates J, Kane J, Lieberman J. Deficits in mismatch negativity in schizophrenia: Predictor of outcome or result of illness progression? Schizophrenia Research. 60: 262. DOI: 10.1016/S0920-9964(03)80401-2 |
0.378 |
|
| 2003 |
McEvoy J, Lieberman J, Perkins D, Hamer R, Sharma T, Zipursky R, Kahn R, Gur R, Centorrino F, Glick I, Green A, Nemeroff C, Rothschild A, Strakowski S, Tohen M, et al. Long-term efficacy and safety of atypical and conventional antipsychotic drugs in first episode schizophrenia Schizophrenia Research. 60: 313. DOI: 10.1016/S0920-9964(03)80257-8 |
0.338 |
|
| 2002 |
Lindenmayer JP, Czobor P, Volavka J, Lieberman JA, Citrome L, Sheitman B, Chakos M, McEvoy JP. Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study. The Journal of Clinical Psychiatry. 63: 931-5. PMID 12416603 DOI: 10.4088/JCP.V63N1011 |
0.429 |
|
| 2002 |
Bilder RM, Volavka J, Czobor P, Malhotra AK, Kennedy JL, Ni X, Goldman RS, Hoptman MJ, Sheitman B, Lindenmayer JP, Citrome L, McEvoy JP, Kunz M, Chakos M, Cooper TB, ... Lieberman JA, et al. Neurocognitive correlates of the COMT Val(158)Met polymorphism in chronic schizophrenia. Biological Psychiatry. 52: 701-7. PMID 12372660 DOI: 10.1016/S0006-3223(02)01416-6 |
0.419 |
|
| 2002 |
Robinson DG, Woerner MG, Alvir JM, Bilder RM, Hinrichsen GA, Lieberman JA. Predictors of medication discontinuation by patients with first-episode schizophrenia and schizoaffective disorder. Schizophrenia Research. 57: 209-19. PMID 12223252 DOI: 10.1016/S0920-9964(01)00312-7 |
0.42 |
|
| 2002 |
Maynard TM, Haskell GT, Lieberman JA, LaMantia AS. 22q11 DS: genomic mechanisms and gene function in DiGeorge/velocardiofacial syndrome. International Journal of Developmental Neuroscience : the Official Journal of the International Society For Developmental Neuroscience. 20: 407-19. PMID 12175881 DOI: 10.1016/S0736-5748(02)00050-3 |
0.314 |
|
| 2002 |
Andersson C, Hamer RM, Lawler CP, Mailman RB, Lieberman JA. Striatal volume changes in the rat following long-term administration of typical and atypical antipsychotic drugs. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 27: 143-51. PMID 12093588 DOI: 10.1016/S0893-133X(02)00412-8 |
0.372 |
|
| 2002 |
Goldstein RZ, Giovannetti T, Schullery M, Zuffante PA, Lieberman JA, Robinson DG, Barr WB, Bilder RM. Neurocognitive correlates of response to treatment in formal thought disorder in patients with first-episode schizophrenia. Neuropsychiatry, Neuropsychology, and Behavioral Neurology. 15: 88-98. PMID 12050471 |
0.352 |
|
| 2002 |
Marder SR, Essock SM, Miller AL, Buchanan RW, Davis JM, Kane JM, Lieberman J, Schooler NR. The Mount Sinai Conference on the Pharmacotherapy of Schizophrenia Schizophrenia Bulletin. 28: 5-16. PMID 12047022 DOI: 10.1093/Oxfordjournals.Schbul.A006926 |
0.523 |
|
| 2002 |
Bilder RM, Goldman RS, Volavka J, Czobor P, Hoptman M, Sheitman B, Lindenmayer JP, Citrome L, McEvoy J, Kunz M, Chakos M, Cooper TB, Horowitz TL, Lieberman JA. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. The American Journal of Psychiatry. 159: 1018-28. PMID 12042192 DOI: 10.1176/appi.ajp.159.6.1018 |
0.373 |
|
| 2002 |
Gunduz H, Wu H, Ashtari M, Bogerts B, Crandall D, Robinson DG, Alvir J, Lieberman J, Kane J, Bilder R. Basal ganglia volumes in first-episode schizophrenia and healthy comparison subjects. Biological Psychiatry. 51: 801-8. PMID 12007454 DOI: 10.1016/S0006-3223(01)01345-2 |
0.495 |
|
| 2002 |
Lieberman J, Stroup S, Schneider L. Prevention of relapse in schizophrenia. The New England Journal of Medicine. 346: 1412-3; author reply. PMID 11987324 |
0.42 |
|
| 2002 |
Curtin F, Stalman SLP, Lieberman J, Schneider L, Csernansky JG, Mahmoud R. Prevention of relapse in schizophrenia [2] (multiple letters) New England Journal of Medicine. 346: 1412-1413. PMID 11987323 DOI: 10.1056/Nejm200205023461816 |
0.511 |
|
| 2002 |
Volavka J, Czobor P, Sheitman B, Lindenmayer JP, Citrome L, McEvoy JP, Cooper TB, Chakos M, Lieberman JA. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. The American Journal of Psychiatry. 159: 255-62. PMID 11823268 DOI: 10.1176/Appi.Ajp.159.2.255 |
0.513 |
|
| 2002 |
Szeszko PR, Strous RD, Goldman RS, Ashtari M, Knuth KH, Lieberman JA, Bilder RM. Neuropsychological correlates of hippocampal volumes in patients experiencing a first episode of schizophrenia. The American Journal of Psychiatry. 159: 217-26. PMID 11823263 DOI: 10.1176/Appi.Ajp.159.2.217 |
0.366 |
|
| 2002 |
Lindenmayer JP, Volavka J, Lieberman J, Sheitman B, Citrome L, Chakos M, Czobor P, Parker B, Iskander A. Olanzapine for schizophrenia refractory to typical and atypical antipsychotics: an open-label, prospective trial. Journal of Clinical Psychopharmacology. 21: 448-53. PMID 11476131 DOI: 10.1097/00004714-200108000-00014 |
0.524 |
|
| 2002 |
Sartorius N, Fleischhacker WW, Gjerris A, Kern U, Knapp M, Leonard BE, Lieberman JA, López-Ibor JJ, Van Raay B, Twomey E, Kupfer DJ, Angst J, Cassano GB, Crow TJ, Freeman H, et al. The usefulness and use of second-generation antipsychotic medications: Preface Current Opinion in Psychiatry. 15: S1-S51. DOI: 10.1097/00001504-200203001-00001 |
0.301 |
|
| 2002 |
Lieberman J, Eure T, Eure A. Sensitization in the pathogenesis and natural history of schizophrenia European Neuropsychopharmacology. 12: 114. DOI: 10.1016/S0924-977X(02)80050-5 |
0.4 |
|
| 2002 |
Lieberman JA, Perkins D, Belger A, Chakos M, Jarskog F, Boteva K, Gilmore J. Erratum: The early stages of schizophrenia: Speculations on pathogenesis, pathophysiology, and therapeuthic approaches (Biological Psychiatry 50:11 (884-897)) Biological Psychiatry. 51. DOI: 10.1016/S0006-3223(02)01310-0 |
0.454 |
|
| 2001 |
Lieberman JA, Perkins D, Belger A, Chakos M, Jarskog F, Boteva K, Gilmore J. The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches. Biological Psychiatry. 50: 884-97. PMID 11743943 DOI: 10.1016/S0006-3223(01)01303-8 |
0.526 |
|
| 2001 |
Sevy S, Robinson DG, Holloway S, Alvir JM, Woerner MG, Bilder R, Goldman R, Lieberman J, Kane J. Correlates of substance misuse in patients with first-episode schizophrenia and schizoaffective disorder Acta Psychiatrica Scandinavica. 104: 367-374. PMID 11722318 DOI: 10.1034/J.1600-0447.2001.00452.X |
0.494 |
|
| 2001 |
Marx CE, Jarskog LF, Lauder JM, Lieberman JA, Gilmore JH. Cytokine effects on cortical neuron MAP-2 immunoreactivity: Implications for schizophrenia Biological Psychiatry. 50: 743-749. PMID 11720692 DOI: 10.1016/S0006-3223(01)01209-4 |
0.347 |
|
| 2001 |
Citrome L, Volavka J, Czobor P, Sheitman B, Lindenmayer JP, McEvoy J, Cooper TB, Chakos M, Lieberman JA. Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia. Psychiatric Services (Washington, D.C.). 52: 1510-4. PMID 11684748 DOI: 10.1176/APPI.PS.52.11.1510 |
0.44 |
|
| 2001 |
Maynard TM, Sikich L, Lieberman JA, LaMantia AS. Neural development, cell-cell signaling, and the "two-hit" hypothesis of schizophrenia. Schizophrenia Bulletin. 27: 457-76. PMID 11596847 DOI: 10.1093/Oxfordjournals.Schbul.A006887 |
0.395 |
|
| 2001 |
Strous RD, Pollack S, Robinson D, Sheitman B, Lieberman JA. Seasonal admission patterns in first episode psychosis, chronic schizophrenia, and nonschizophrenic psychoses. The Journal of Nervous and Mental Disease. 189: 642-4. PMID 11580010 DOI: 10.1097/00005053-200109000-00012 |
0.477 |
|
| 2001 |
Chakos M, Lieberman J, Hoffman E, Bradford D, Sheitman B. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: A review and meta-analysis of randomized trials American Journal of Psychiatry. 158: 518-526. PMID 11282684 DOI: 10.1176/Appi.Ajp.158.4.518 |
0.489 |
|
| 2001 |
Lieberman J, Chakos M, Wu H, Alvir J, Hoffman E, Robinson D, Bilder R. Longitudinal study of brain morphology in first episode schizophrenia. Biological Psychiatry. 49: 487-99. PMID 11257234 DOI: 10.1016/S0006-3223(01)01067-8 |
0.517 |
|
| 2001 |
Miyamoto S, Mailman RB, Lieberman JA, Duncan GE. Blunted brain metabolic response to ketamine in mice lacking D(1A) dopamine receptors. Brain Research. 894: 167-80. PMID 11251190 DOI: 10.1016/S0006-8993(01)01991-6 |
0.314 |
|
| 2001 |
Masellis M, Basile VS, Meltzer HY, Lieberman JA, Sevy S, Goldman DA, Hamblin MW, Macciardi FM, Kennedy JL. Lack of association between the T-->C 267 serotonin 5-HT6 receptor gene (HTR6) polymorphism and prediction of response to clozapine in schizophrenia. Schizophrenia Research. 47: 49-58. PMID 11163544 DOI: 10.1016/S0920-9964(00)00016-5 |
0.329 |
|
| 2001 |
Bilder R, Goldman R, Volavka J, Czobor P, Hoptman M, Sheitman B, Lindenmayer J, Citrome L, McEvoy J, Kunz M, Chakos M, Lieberman J. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol on treatment-resistant patients with schizophrenia and schizoaffective disorder European Neuropsychopharmacology. 11: S256. DOI: 10.1016/S0924-977X(01)80300-X |
0.4 |
|
| 2001 |
Strous R, Alvir J, Robinson D, Sheitman B, Chakos M, Lieberman J. The association of premorbid function in schizophrenia with baseline symptomatology, treatment response and medication side-effects European Neuropsychopharmacology. 11: S254. DOI: 10.1016/S0924-977X(01)80293-5 |
0.395 |
|
| 2000 |
Lewis DA, Lieberman JA. Catching up on schizophrenia: Natural history and neurobiology Neuron. 28: 325-334. PMID 11144342 DOI: 10.1016/S0896-6273(00)00111-2 |
0.507 |
|
| 2000 |
Sheitman BB, Murray MG, Snyder JA, Silva S, Goldman R, Chakos M, Volavka J, Lieberman JA. IQ scores of treatment-resistant schizophrenia patients before and after the onset of the illness. Schizophrenia Research. 46: 203-7. PMID 11120432 DOI: 10.1016/S0920-9964(00)00034-7 |
0.385 |
|
| 2000 |
Javitt DC, Shelley AM, Silipo G, Lieberman JA. Deficits in auditory and visual context-dependent processing in schizophrenia: defining the pattern. Archives of General Psychiatry. 57: 1131-7. PMID 11115326 DOI: 10.1001/Archpsyc.57.12.1131 |
0.412 |
|
| 2000 |
Jarskog LF, Gilmore JH, Selinger ES, Lieberman JA. Cortical Bcl-2 protein expression and apoptotic regulation in schizophrenia Biological Psychiatry. 48: 641-650. PMID 11032975 DOI: 10.1016/S0006-3223(00)00988-4 |
0.463 |
|
| 2000 |
Lieberman JA, Golden R, Stroup S, McEvoy J. Drugs of the psychopharmacological revolution in clinical psychiatry. Psychiatric Services (Washington, D.C.). 51: 1254-8. PMID 11013323 DOI: 10.1176/Appi.Ps.51.10.1254 |
0.351 |
|
| 2000 |
Basile VS, Ozdemir V, Masellis M, Walker ML, Meltzer HY, Lieberman JA, Potkin SG, Alva G, Kalow W, Macciardi FM, Kennedy JL. A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene: association with tardive dyskinesia in schizophrenia. Molecular Psychiatry. 5: 410-7. PMID 10889552 DOI: 10.1038/Sj.Mp.4000736 |
0.309 |
|
| 2000 |
Perkins DO, Leserman J, Jarskog LF, Graham K, Kazmer J, Lieberman JA. Characterizing and dating the onset of symptoms in psychotic illness: The Symptom Onset in Schizophrenia (SOS) inventory Schizophrenia Research. 44: 1-10. PMID 10867307 DOI: 10.1016/S0920-9964(99)00161-9 |
0.476 |
|
| 2000 |
Szeszko PR, Bilder RM, Lencz T, Ashtari M, Goldman RS, Reiter G, Wu H, Lieberman JA. Reduced anterior cingulate gyrus volume correlates with executive dysfunction in men with first-episode schizophrenia. Schizophrenia Research. 43: 97-108. PMID 10858628 DOI: 10.1016/S0920-9964(99)00155-3 |
0.405 |
|
| 2000 |
Bilder RM, Goldman RS, Robinson D, Reiter G, Bell L, Bates JA, Pappadopulos E, Willson DF, Alvir JM, Woerner MG, Geisler S, Kane JM, Lieberman JA. Neuropsychology of first-episode schizophrenia: initial characterization and clinical correlates. The American Journal of Psychiatry. 157: 549-59. PMID 10739413 DOI: 10.1176/Appi.Ajp.157.4.549 |
0.409 |
|
| 2000 |
Vincent JB, Neves-Pereira ML, Paterson AD, Yamamoto E, Parikh SV, Macciardi F, Gurling HM, Potkin SG, Pato CN, Macedo A, Kovacs M, Davies M, Lieberman JA, Meltzer HY, Petronis A, et al. An unstable trinucleotide-repeat region on chromosome 13 implicated in spinocerebellar ataxia: a common expansion locus. American Journal of Human Genetics. 66: 819-29. PMID 10712198 DOI: 10.1086/302803 |
0.315 |
|
| 2000 |
Miyamoto S, Leipzig JN, Lieberman JA, Duncan GE. Effects of ketamine, MK-801, and amphetamine on regional brain 2-deoxyglucose uptake in freely moving mice. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 22: 400-12. PMID 10700659 DOI: 10.1016/S0893-133X(99)00127-X |
0.341 |
|
| 2000 |
Gunduz H, Woerner MG, Alvir JM, Degreef G, Lieberman JA. Obstetric complications in schizophrenia, schizoaffective disorder and normal comparison subjects. Schizophrenia Research. 40: 237-43. PMID 10638862 DOI: 10.1016/S0920-9964(99)00054-7 |
0.502 |
|
| 2000 |
Mohr P, Volavka J, Lieberman J, Czobor P, McEvoy J, Lindenmayer J, Citrome L, Sheitman B. FC09.05 Clozapine, olanzapine, risperidone, and haloperidol in refractory schizophrenia European Psychiatry. 15: 284s-284s. DOI: 10.1016/S0924-9338(00)94238-X |
0.527 |
|
| 2000 |
Lewis DA, Lieberman JA. Catching Up on Schizophrenia Neuron. 28: 325-334. DOI: 10.1016/S0896-6273(00)00111-2 |
0.422 |
|
| 2000 |
Chakos M, Charles C, Silva S, Sheitman B, Schobel S, Bradford D, Lieberman J. 84. Clinical correlates of structural brain abnormalities in schizophrenia Biological Psychiatry. 47: S25-S26. DOI: 10.1016/S0006-3223(00)00346-2 |
0.341 |
|
| 1999 |
Umbricht D, Javitt D, Novak G, Bates J, Pollack S, Lieberman J, Kane J. Effects of risperidone on auditory event-related potentials in schizophrenia. The International Journal of Neuropsychopharmacology / Official Scientific Journal of the Collegium Internationale Neuropsychopharmacologicum (Cinp). 2: 299-304. PMID 11285146 DOI: 10.1017/S1461145799001595 |
0.439 |
|
| 1999 |
Bilder RM, Wu H, Bogerts B, Ashtari M, Robinson D, Woerner M, Lieberman JA, Degreef G. Cerebral volume asymmetries in schizophrenia and mood disorders: a quantitative magnetic resonance imaging study. International Journal of Psychophysiology : Official Journal of the International Organization of Psychophysiology. 34: 197-205. PMID 10610044 DOI: 10.1016/S0167-8760(99)00077-X |
0.462 |
|
| 1999 |
Yui K, Goto K, Ikemoto S, Ishiguro T, Angrist B, Duncan GE, Sheitman BB, Lieberman JA, Bracha SH, Ali SF. Neurobiological basis of relapse prediction in stimulant-induced psychosis and schizophrenia: the role of sensitization. Molecular Psychiatry. 4: 512-23. PMID 10578232 DOI: 10.1038/Sj.Mp.4000575 |
0.403 |
|
| 1999 |
Hinrichsen GA, Lieberman JA. Family attributions and coping in the prediction of emotional adjustment in family members of patients with first-episode schizophrenia Acta Psychiatrica Scandinavica. 100: 359-366. PMID 10563453 DOI: 10.1111/J.1600-0447.1999.Tb10879.X |
0.355 |
|
| 1999 |
Duncan GE, Zorn S, Lieberman JA. Mechanisms of typical and atypical antipsychotic drug action in relation to dopamine and NMDA receptor hypofunction hypotheses of schizophrenia. Molecular Psychiatry. 4: 418-28. PMID 10523814 DOI: 10.1038/Sj.Mp.4000581 |
0.357 |
|
| 1999 |
Lieberman JA. Is schizophrenia a neurodegenerative disorder? A clinical and neurobiological perspective Biological Psychiatry. 46: 729-739. PMID 10494440 DOI: 10.1016/S0006-3223(99)00147-X |
0.511 |
|
| 1999 |
Dawkins K, Lieberman JA, Lebowitz BD, Hsiao JK. Antipsychotics: Past and Future: National Institute of Mental Health Division of Services and Intervention Research Workshop, July 14, 1998. Schizophrenia Bulletin. 25: 395-405. PMID 10416740 DOI: 10.1093/Oxfordjournals.Schbul.A033387 |
0.363 |
|
| 1999 |
Keefe RSE, Silva SG, Perkins DO, Lieberman JA. The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: A review and meta-analysis Schizophrenia Bulletin. 25: 201-222. PMID 10416727 DOI: 10.1093/Oxfordjournals.Schbul.A033374 |
0.518 |
|
| 1999 |
Alvir JM, Woerner MG, Gunduz H, Degreef G, Lieberman JA. Obstetric complications predict treatment response in first-episode schizophrenia. Psychological Medicine. 29: 621-7. PMID 10405083 DOI: 10.1017/S0033291799008363 |
0.541 |
|
| 1999 |
Vincent JB, Petronis A, Strong E, Parikh SV, Meltzer HY, Lieberman J, Kennedy JL. Analysis of genome-wide CAG/CTG repeats, and at SEF2-1B and ERDA1 in schizophrenia and bipolar affective disorder. Molecular Psychiatry. 4: 229-34. PMID 10395212 DOI: 10.1038/Sj.Mp.4000498 |
0.314 |
|
| 1999 |
Basile VS, Masellis M, Badri F, Paterson AD, Meltzer HY, Lieberman JA, Potkin SG, Macciardi F, Kennedy JL. Association of the MscI polymorphism of the dopamine D3 receptor gene with tardive dyskinesia in schizophrenia. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 21: 17-27. PMID 10379516 DOI: 10.1016/S0893-133X(98)00114-6 |
0.385 |
|
| 1999 |
Lee H, Tarazi FI, Chakos M, Wu H, Redmond M, Alvir JM, Kinon BJ, Bilder R, Creese I, Lieberman JA. Effects of chronic treatment with typical and atypical antipsychotic drugs on the rat striatum. Life Sciences. 64: 1595-602. PMID 10328519 DOI: 10.1016/S0024-3205(99)00106-X |
0.346 |
|
| 1999 |
Szeszko PR, Bilder RM, Lencz T, Pollack S, Alvir JM, Ashtari M, Wu H, Lieberman JA. Investigation of frontal lobe subregions in first-episode schizophrenia. Psychiatry Research. 90: 1-15. PMID 10320207 DOI: 10.1016/S0925-4927(99)00002-5 |
0.413 |
|
| 1999 |
Robinson DG, Woerner MG, Alvir JMJ, Geisler S, Koreen A, Sheitman B, Chakos M, Mayerhoff D, Bilder R, Goldman R, Lieberman JA. Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder American Journal of Psychiatry. 156: 544-549. PMID 10200732 DOI: 10.1176/Ajp.156.4.544 |
0.393 |
|
| 1999 |
Szeszko PR, Bilder RM, Dunlop JA, Walder DJ, Lieberman JA. Longitudinal assessment of methylphenidate effects on oral word production and symptoms in first-episode schizophrenia at acute and stabilized phases. Biological Psychiatry. 45: 680-6. PMID 10187997 DOI: 10.1016/S0006-3223(98)00258-3 |
0.41 |
|
| 1999 |
Robinson D, Woerner MG, Alvir JMJ, Bilder R, Goldman R, Geisler S, Koreen A, Sheitman B, Chakos M, Mayerhoff D, Lieberman JA. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder Archives of General Psychiatry. 56: 241-247. PMID 10078501 DOI: 10.1001/Archpsyc.56.3.241 |
0.486 |
|
| 1999 |
Sanger TM, Lieberman JA, Tohen M, Grundy S, Beasley C, Tollefson GD. Olanzapine versus haloperidol treatment in first-episode psychosis. The American Journal of Psychiatry. 156: 79-87. PMID 9892301 DOI: 10.1176/AJP.156.1.79 |
0.377 |
|
| 1999 |
Chakos MH, Shirakawa O, Lieberman J, Lee H, Bilder R, Tamminga CA. Striatal enlargement in rats chronically treated with neuroleptic. Biological Psychiatry. 44: 675-84. PMID 9798070 DOI: 10.1016/S0006-3223(98)00029-8 |
0.339 |
|
| 1999 |
Özdemir V, Masellis M, Basile VS, Kalow W, Meltzer HY, Lieberman JA, Kennedy JL. Variability in Response to Clozapine: Potential Role of Cytochrome P450 1A2 and the Dopamine D4 Receptor Gene Cns Spectrums. 4: 30-34, 47-56. DOI: 10.1017/S109285290001186X |
0.332 |
|
| 1998 |
Lieberman JA, Mailman RB, Duncan G, Sikich L, Chakos M, Nichols DE, Kraus JE. Serotonergic basis of antipsychotic drug effects in schizophrenia. Biological Psychiatry. 44: 1099-117. PMID 9836014 DOI: 10.1016/S0006-3223(98)00187-5 |
0.398 |
|
| 1998 |
Woerner MG, Alvir JMJ, Saltz BL, Lieberman JA, Kane JM. Prospective study of tardive dyskinesia in the elderly: Rates and risk factors American Journal of Psychiatry. 155: 1521-1528. PMID 9812112 DOI: 10.1176/Ajp.155.11.1521 |
0.372 |
|
| 1998 |
Umbricht D, Javitt D, Novak G, Bates J, Pollack S, Lieberman J, Kane J. Effects of clozapine on auditory event-related potentials in schizophrenia. Biological Psychiatry. 44: 716-25. PMID 9798075 DOI: 10.1016/S0006-3223(97)00524-6 |
0.466 |
|
| 1998 |
Sheitman BB, Lieberman JA. The natural history and pathophysiology of treatment resistant schizophrenia Journal of Psychiatric Research. 32: 143-150. PMID 9793867 DOI: 10.1016/S0022-3956(97)00052-6 |
0.417 |
|
| 1998 |
Marx CE, Lieberman JA. Psychoneuroendocrinology of schizophrenia Psychiatric Clinics of North America. 21: 413-434. PMID 9670234 DOI: 10.1016/S0193-953X(05)70013-7 |
0.418 |
|
| 1998 |
Snyder PJ, Bogerts B, Wu H, Bilder RM, Deoras KS, Lieberman JA. Absence of the adhesio interthalamica as a marker of early developmental neuropathology in schizophrenia: an MRI and postmortem histologic study. Journal of Neuroimaging : Official Journal of the American Society of Neuroimaging. 8: 159-63. PMID 9664852 DOI: 10.1111/Jon199883159 |
0.436 |
|
| 1998 |
Masellis M, Basile V, Meltzer HY, Lieberman JA, Sevy S, Macciardi FM, Cola P, Howard A, Badri F, Nöthen MM, Kalow W, Kennedy JL. Serotonin subtype 2 receptor genes and clinical response to clozapine in schizophrenia patients. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 19: 123-32. PMID 9629566 DOI: 10.1016/S0893-133X(98)00007-4 |
0.331 |
|
| 1998 |
Lieberman JA, Sheitman B, Chakos M, Robinson D, Schooler N, Keith S. The development of treatment resistance in patients with schizophrenia: a clinical and pathophysiologic perspective. Journal of Clinical Psychopharmacology. 18: 20S-4S. PMID 9555612 DOI: 10.1097/00004714-199804001-00005 |
0.401 |
|
| 1998 |
Anderson C, Chakos M, Mailman R, Lieberman J. Emerging roles for novel antipsychotic medications in the treatment of schizophrenia Psychiatric Clinics of North America. 21: 151-179. PMID 9551495 DOI: 10.1016/S0193-953X(05)70365-8 |
0.55 |
|
| 1998 |
Miller CH, Mohr F, Umbricht D, Woerner M, Fleischhacker WW, Lieberman JA. The prevalence of acute extrapyramidal signs and symptoms in patients treated with clozapine, risperidone, and conventional antipsychotics Journal of Clinical Psychiatry. 59: 69-75. PMID 9501888 DOI: 10.1016/S0920-9964(97)82764-8 |
0.418 |
|
| 1998 |
Perkins DO, Lieberman JA. Medical complications and selectivity of therapeutic response to atypical antipsychotic drugs American Journal of Psychiatry. 155: 272-276. PMID 9464209 DOI: 10.1176/Ajp.155.2.272 |
0.318 |
|
| 1998 |
Bradford DW, Chakos MH, Sheitman BB, Lieberman JA. Atypical Antipsychotic Drugs in Treatment-Refractory Schizophrenia Psychiatric Annals. 28: 618-626. DOI: 10.3928/0048-5713-19981101-06 |
0.517 |
|
| 1998 |
Lieberman JA. Pathophysiology in the clinical course of schizophrenia International Clinical Psychopharmacology. 13: S3-S6. DOI: 10.1097/00004850-199801001-00002 |
0.488 |
|
| 1998 |
Zuffante P, Wu H, Reiter G, Lieberman J, Bilder R. 437. Language and superior temporal gyrus volumes in schizophrenia Biological Psychiatry. 43: S131. DOI: 10.1016/S0006-3223(98)90885-X |
0.316 |
|
| 1998 |
Grube B, Goldman R, Alvir J, Bergman A, Bilder R, Lieberman J. 379. Symptom dimensions in first-episode schizophrenia: A longitudinal, confirmatory factor analytic study Biological Psychiatry. 43: S114. DOI: 10.1016/S0006-3223(98)90827-7 |
0.365 |
|
| 1998 |
Crandall D, Bilder R, Goldman R, Lieberman J. 233. Effects of dopaminergic modulation on trait-like redundancy in schizophrenia Biological Psychiatry. 43: S69. DOI: 10.1016/S0006-3223(98)90681-3 |
0.393 |
|
| 1998 |
Goldman R, Bilder R, Pappadopulos E, Reiter G, Alvir J, Robinson D, Lieberman J. 35. Neuropsychological prediction of functional outcome in first-episode schizophrenia Biological Psychiatry. 43: S11. DOI: 10.1016/S0006-3223(98)90483-8 |
0.339 |
|
| 1998 |
Bradford DW, Chakos MH, Sheitman BB, Lieberman JA. Atypical antipsychotic drugs in treatment-refractory schizophrenia Psychiatric Annals. 28: 618-626. |
0.421 |
|
| 1997 |
Sheitman BB, Lee H, Strauss R, Lieberman JA. The evaluation and treatment of first-episode psychosis Schizophrenia Bulletin. 23: 653-661. PMID 9366001 DOI: 10.1093/Schbul/23.4.653 |
0.417 |
|
| 1997 |
Lieberman JA, Sheitman BB, Kinon BJ. Neurochemical sensitization in the pathophysiology of schizophrenia: Deficits and dysfunction in neuronal regulation and plasticity Neuropsychopharmacology. 17: 205-229. PMID 9326746 DOI: 10.1016/S0893-133X(97)00045-6 |
0.53 |
|
| 1997 |
Schooler NR, Keith SJ, Severe JB, Matthews SM, Bellack AS, Glick ID, Hargreaves WA, Kane JM, Ninan PT, Frances A, Jacobs M, Lieberman JA, Mance R, Simpson GM, Woerner MG. Relapse and rehospitalization during maintenance treatment of schizophrenia: The effects of dose reduction and family treatment Archives of General Psychiatry. 54: 453-463. PMID 9152099 DOI: 10.1001/Archpsyc.1997.01830170079011 |
0.376 |
|
| 1997 |
Paterson AD, Ying DJ, Petronis A, Schoots O, Lieberman JA, Van Tol HH, Kennedy JL. A PstI restriction fragment length polymorphism in the 5' untranslated region of DRD4 is not associated with schizophrenia. Psychiatric Genetics. 6: 191-3. PMID 9149324 DOI: 10.1097/00041444-199624000-00004 |
0.405 |
|
| 1997 |
Herz MI, Liberman RP, McGlashan TH, Lieberman JA, Wyatt RJ, Marder SR, Wang P, Allgulander C, Baldessarini RJ, Balon R, Bellack AS, Berlin CMJ, Blackington CH, Buckley P, Carlson DG, et al. Practice guideline for the treatment of patients with schizophrenia American Journal of Psychiatry. 154: 1-63. PMID 9090368 DOI: 10.1176/Ajp.154.4.1 |
0.496 |
|
| 1997 |
Koreen AR, Lieberman JA, Alvir J, Chakos M. The behavioral effect of m-chlorophenylpiperazine (mCPP) and methylphenidate in first-episode schizophrenia and normal controls Neuropsychopharmacology. 16: 61-68. PMID 8981389 DOI: 10.1016/0920-9964(95)95480-W |
0.451 |
|
| 1997 |
Gilmore JH, Sikich L, Lieberman JA. Neuroimaging, neurodevelopment, and schizophrenia Child and Adolescent Psychiatric Clinics of North America. 6: 325-341. DOI: 10.1016/S1056-4993(18)30307-9 |
0.513 |
|
| 1997 |
Waltrip RW, Lieberman J, Robinson D, Bilder RM, Alvir JM, King LR, Summerfelt A, Rubin SA, Carbone KM. First episode schizophrenia and borna disease virus Schizophrenia Research. 24: 261. DOI: 10.1016/S0920-9964(97)82754-5 |
0.453 |
|
| 1997 |
Gunduz H, Woerner MG, Alvir JMJ, Lieberman JA. Obstetric complications in schizophrenia, affective disorder and normal controls Schizophrenia Research. 24: 251. DOI: 10.1016/S0920-9964(97)82721-1 |
0.466 |
|
| 1997 |
Umbricht D, Javitt D, Bates J, Pollak S, Lieberman J, Kane J. Event-related potentials (ERP) during a visual working memory task in first episode and chronic schizophrenia Schizophrenia Research. 24: 239. DOI: 10.1016/S0920-9964(97)82689-8 |
0.368 |
|
| 1997 |
Umbricht D, Javitt D, Bates J, Pollak S, Lieberman J, Kane J. Auditory event-related potentials (ERP) in first episode and chronic schizophrenia Schizophrenia Research. 24: 238-239. DOI: 10.1016/S0920-9964(97)82688-6 |
0.44 |
|
| 1997 |
Alvir JMJ, Woerner MG, Gunduz H, Lieberman JA. Obstetric complications predict treatment response in first episode schizophrenia Schizophrenia Research. 24: 204-205. DOI: 10.1016/S0920-9964(97)82587-X |
0.482 |
|
| 1997 |
Robison DG, Lieberman JA, Sheitman B, Alvir JMJ, Kane JM. Pilot study of atypical antipsychotic agents in first episode schizophrenia Schizophrenia Research. 24: 196. DOI: 10.1016/S0920-9964(97)82561-3 |
0.513 |
|
| 1997 |
Tollefson GD, Sanger TM, Lieberman JA. Olanzapine versus haloperidol in the treatment of first episode psychosis Schizophrenia Research. 24: 193. DOI: 10.1016/S0920-9964(97)82552-2 |
0.402 |
|
| 1997 |
Woerner MG, Gunduz H, Alvir JM, Bilder R, Lieberman JA. Obstetric complications and brain MRI findings in schizophrenia Schizophrenia Research. 24: 160. DOI: 10.1016/S0920-9964(97)82460-7 |
0.447 |
|
| 1997 |
Szeszko P, Lencz T, Bilder R, Redmond M, Wu H, Lieberman J. Parcellation of the frontal lobes in first-episode schizophrenia Schizophrenia Research. 24: 158. DOI: 10.1016/S0920-9964(97)82454-1 |
0.502 |
|
| 1997 |
Lencz T, Redmond MP, Bookstein FL, Wu H, Bilder RM, Ashtari M, Lieberman JA. MRI landmark shape analysis of neuroanatomy in first-episode schizophrenia Schizophrenia Research. 24: 151. DOI: 10.1016/S0920-9964(97)82431-0 |
0.49 |
|
| 1997 |
Crandall DT, Szeszko PR, Bilder RM, Strous R, Lieberman JA. Reduced anterior hippocampal volumes are associated with alternating response patterns in first episode schizophrenia Schizophrenia Research. 24: 141. DOI: 10.1016/S0920-9964(97)82402-4 |
0.474 |
|
| 1997 |
Barr WB, Bilder RM, Goldman RS, Lieberman JA. Neuropsychological comparison of executive functions in first-episode schizophrenia and temporal lobe epilepsy Schizophrenia Research. 24: 98. DOI: 10.1016/S0920-9964(97)82265-7 |
0.44 |
|
| 1997 |
Vincent JB, Meltzer H, Lieberman J, Breschel T, McGinnis M, Macedo A, Azevedo M, Pato C, Torrey E, Gottesman I, Petronis A, Kennedy J. Large or expanded CAG/CTG trinucleotide repeats as an etiological factor in schizophrenia Schizophrenia Research. 24: 55. DOI: 10.1016/S0920-9964(97)82157-3 |
0.393 |
|
| 1997 |
Lieberman JA. Co-morbidity issues in the treatment of schizophrenia Biological Psychiatry. 42: 266S. DOI: 10.1016/S0006-3223(97)88033-X |
0.509 |
|
| 1997 |
Lieberman JA. Atypical antipsychotic drug treatment in the early stages of schizophrenia Biological Psychiatry. 42: 200S. DOI: 10.1016/S0006-3223(97)87739-6 |
0.486 |
|
| 1997 |
Lieberman J, Chatterjee A, Chakos M, Koreen A, Geisler S, Sheitman B, Woemer M, Kane JM, Alvir J. Extrapyramidal signs in dyskinesia in first episode schizophrenia Biological Psychiatry. 42. DOI: 10.1016/S0006-3223(97)87447-1 |
0.523 |
|
| 1997 |
Lieberman J, Koreen A, Geisler S, Bilder R, Bogerts B, Alvir J, Cooper T. The psychobiology of first episode schizophrenia Biological Psychiatry. 42: 61S-62S. DOI: 10.1016/S0006-3223(97)87131-4 |
0.424 |
|
| 1996 |
Kinon BJ, Lieberman JA. Mechanisms of action of atypical antipsychotic drugs: A critical analysis Psychopharmacology. 124: 2-34. PMID 8935797 DOI: 10.1007/Bf02245602 |
0.425 |
|
| 1996 |
Lieberman JA, Alvir JM, Koreen A, Geisler S, Chakos M, Sheitman B, Woerner M. Psychobiologic correlates of treatment response in schizophrenia Neuropsychopharmacology. 14: 13S-21S. PMID 8866739 DOI: 10.1016/0893-133X(95)00200-W |
0.488 |
|
| 1996 |
Sasaki T, Macciardi FM, Badri F, Verga M, Meltzer HY, Lieberman J, Howard A, Bean G, Joffe RT, Hudson CJ, Kennedy JL. No evidence for association of dopamine D2 receptor variant (Ser311/Cys311) with major psychosis. American Journal of Medical Genetics. 67: 415-7. PMID 8837713 DOI: 10.1002/(Sici)1096-8628(19960726)67:4<415::Aid-Ajmg18>3.0.Co;2-M |
0.438 |
|
| 1996 |
Kennedy JL, Billett EA, Macciardi FM, Verga M, Parsons TJ, Meltzer HY, Lieberman J, Buchanan JA. Association study of dopamine D3 receptor gene and schizophrenia. American Journal of Medical Genetics. 60: 558-62. PMID 8825896 DOI: 10.1002/Ajmg.1320600615 |
0.371 |
|
| 1996 |
Shelley AM, Grochowski S, Lieberman JA, Javitt DC. Premature disinhibition of P3 generation in schizophrenia. Biological Psychiatry. 39: 714-9. PMID 8731459 DOI: 10.1016/0006-3223(95)00222-7 |
0.358 |
|
| Show low-probability matches. |